CA2236022A1 - Virus assay method - Google Patents
Virus assay method Download PDFInfo
- Publication number
- CA2236022A1 CA2236022A1 CA 2236022 CA2236022A CA2236022A1 CA 2236022 A1 CA2236022 A1 CA 2236022A1 CA 2236022 CA2236022 CA 2236022 CA 2236022 A CA2236022 A CA 2236022A CA 2236022 A1 CA2236022 A1 CA 2236022A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- seq
- primers
- human parainfluenza
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 64
- 238000003556 assay Methods 0.000 title description 44
- 238000000034 method Methods 0.000 claims abstract description 112
- 239000000523 sample Substances 0.000 claims abstract description 109
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 72
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims abstract description 45
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 45
- 239000012472 biological sample Substances 0.000 claims abstract description 39
- 241001500351 Influenzavirus A Species 0.000 claims abstract description 29
- 241001500350 Influenzavirus B Species 0.000 claims abstract description 28
- 230000000295 complement effect Effects 0.000 claims abstract description 13
- 230000009385 viral infection Effects 0.000 claims abstract description 6
- 239000013615 primer Substances 0.000 claims description 158
- 241000726041 Human respirovirus 1 Species 0.000 claims description 92
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 241000712003 Human respirovirus 3 Species 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 230000003321 amplification Effects 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 42
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 42
- 238000009396 hybridization Methods 0.000 claims description 36
- 239000002299 complementary DNA Substances 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 28
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 27
- 239000002751 oligonucleotide probe Substances 0.000 claims description 27
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000002987 primer (paints) Substances 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 19
- 241001559187 Human rubulavirus 2 Species 0.000 claims description 16
- 101150008820 HN gene Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000012408 PCR amplification Methods 0.000 claims description 9
- 239000003155 DNA primer Substances 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 6
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 101150076514 NS gene Proteins 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 abstract description 21
- 125000003729 nucleotide group Chemical group 0.000 abstract description 21
- 108091034117 Oligonucleotide Proteins 0.000 description 70
- 239000000047 product Substances 0.000 description 65
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 239000000243 solution Substances 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000890 antigenic effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000010839 reverse transcription Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000004925 denaturation Methods 0.000 description 11
- 230000036425 denaturation Effects 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241001514767 Respiratory syncytial virus type A Species 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000037798 influenza B Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940094991 herring sperm dna Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010066717 Q beta Replicase Proteins 0.000 description 2
- 241000165108 Respiratory syncytial virus type B Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PMJHNEFCWLUZBC-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-1,3-dien-1-amine Chemical compound CC1=C(N)C(C)(C)CC(C=2C=C(C)C(N)=CC=2)=C1 PMJHNEFCWLUZBC-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- VWJFQGXPYOPXJH-ZLUOBGJFSA-N Asn-Cys-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)C(=O)N VWJFQGXPYOPXJH-ZLUOBGJFSA-N 0.000 description 1
- BZWRLDPIWKOVKB-ZPFDUUQYSA-N Asn-Leu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BZWRLDPIWKOVKB-ZPFDUUQYSA-N 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- XBELMDARIGXDKY-GUBZILKMSA-N Cys-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)N XBELMDARIGXDKY-GUBZILKMSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- RGJKYNUINKGPJN-RWRJDSDZSA-N Glu-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)N RGJKYNUINKGPJN-RWRJDSDZSA-N 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 101100339442 Human parainfluenza 2 virus HN gene Proteins 0.000 description 1
- 241001559186 Human rubulavirus 4 Species 0.000 description 1
- HZMLFETXHFHGBB-UGYAYLCHSA-N Ile-Asn-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZMLFETXHFHGBB-UGYAYLCHSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101900330348 Influenza A virus Matrix protein 1 Proteins 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- QPRQGENIBFLVEB-BJDJZHNGSA-N Leu-Ala-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O QPRQGENIBFLVEB-BJDJZHNGSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- NTEVEUCLFMWSND-SRVKXCTJSA-N Lys-Arg-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O NTEVEUCLFMWSND-SRVKXCTJSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- VYXIKLFLGRTANT-HRCADAONSA-N Met-Tyr-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N VYXIKLFLGRTANT-HRCADAONSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101800000511 Non-structural protein 2 Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- XZQYIJALMGEUJD-OEAJRASXSA-N Phe-Lys-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZQYIJALMGEUJD-OEAJRASXSA-N 0.000 description 1
- KCIKTPHTEYBXMG-BVSLBCMMSA-N Phe-Trp-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KCIKTPHTEYBXMG-BVSLBCMMSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KLSOMAFWRISSNI-OSUNSFLBSA-N Pro-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 KLSOMAFWRISSNI-OSUNSFLBSA-N 0.000 description 1
- RPLMFKUKFZOTER-AVGNSLFASA-N Pro-Met-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1 RPLMFKUKFZOTER-AVGNSLFASA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- IFPBAGJBHSNYPR-ZKWXMUAHSA-N Ser-Ile-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O IFPBAGJBHSNYPR-ZKWXMUAHSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710126110 Surface protein F Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 241000724822 Teia Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- UHBPFYOQQPFKQR-JHEQGTHGSA-N Thr-Gln-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O UHBPFYOQQPFKQR-JHEQGTHGSA-N 0.000 description 1
- BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- RRVUOLRWIZXBRQ-IHPCNDPISA-N Trp-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RRVUOLRWIZXBRQ-IHPCNDPISA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047468 Viral lower respiratory tract infections Diseases 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 108010088716 attachment protein G Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method for evaluating a sample for the presence or absence of multiple virus infections is disclosed. In one embodiment, this method comprises the step of evaluating a biological sample for nucleic acid sequences complementary to nucleotide primers and probes derived from the sequences of human parainfluenza virus (1, 2 and 3), respiratory syncytial virus A and B and influenza virus A and B. In another embodiment, the invention is an improved PCR method.
Description
VlKU~ ASS~Y ~h~ V
Field of the Invention In general, the present invention relates to assays for hllm~n parainfluenza virus combined with assays for other disease-causing viruses. In particular, the present invention relates to amplification-based and non-amplification-based assays for parainfluenza virus-l, 2 and 3 co~ined with assays for respiratory syncytial virus A and B and influenza virus A
and B.
Back~round ~llm~n parainfluenza virus type one (HPIV-1) is a major cause of lower respiratory tract infections (~RI~ in infants, young children, and the immunocompromised (Henrickson, K. J., l~Lower respiratory viral infections in immunocompetent children," pp. 59-96, In Aronoff SC (ed), Advances in Pediatric Infectious Diseases. ~osby-Year Book, Chicago, Illinois, 1994; Henrickson, K. J., et al., Parainfluenza. In:
Mandell, Bennet D. (ed) PrinciPles and Practices of Infectious Diseases, Edition 4, Churchill Livingston, New York, 1994).
This virus has world-wide distribution and probably contributes significantly to childhood mortality in the developing world (Henrickson, K. J., su~ra, lg94; Henrickson, K. J., et al., suPra, 1994). In the United States, we have ~mo~trated significant morbidity and cost attributable to HPIV-1 epidemics (Henrickson, K. J., et al., "Epidemiology and cost of hllm~n parainfluenza virus types one and two infections in young children," Clin. Infect. Dis. 18:770-9, 1994).
During these epidemics, approximately 100,000 children less than five years of age are seen in emergency rooms and approximately 35,000 are hospitalized at a co~bined cost of approximately $90,000,000 (Henrickson, K. J., et al., suPra, 1994). Currently, there is no specific therapy or vaccine for any HPIV.
We recently reported that HPIV-1 collected over a 26-year period in a single city ~em~trated different genotypes and that one of these genotypes (A) had genotype-~pecific antigenic SUBSTITUTE SHEET ~RULE 26) W O 97/16570 PCT~US96/17405 markers detectable using MAbs and human sera (Henrickson, K.J., "Monoclonal antibodies to human parainfluenza virus type 1 detect major antigenic changes in clinical isolates," J.
Infect. Dis. 164:1128-34, 1991; Henrickson, K. J., et al., "Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: Analysis of 12 clinical isolates," J. Infect. Dis. 164:1128-34, 1992). Subsequently, others found similar antigenic changes in HPIV-1, and one report failed to find genotypes or antigenic markers over a nine-year period (Komada, H., et al., "Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by monoclonal antibodies," J. Gen. Virol. 73:875-84, 1992;
Hetherington, S. V., et al., "Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages," J. Infect. Dis. 169:248-52, 1994).
HPIV-2 outbreaks occur either biennially or yearly (B.
Murphy, et al., "Seasonal pattern in childhood viral lower respiratory tract infections in Melbourne," Med. J. Australia 1:22-24, 1980; M. A. Downham, et al., "Diagnosis and clinical significance of parainfluenza virus infections in children,"
Arch. Dis. Child 49:8-15, 1974; P. Wright, "Parainfluenza viruses." In: R. B. Belshe ed. Textbook of Human Virology.
Littleton, MA: PSG Publishing pp. 299-310, 1984), the majority of them appear in fall to early winter. HPIV-2 is a frequent cause of croup. It causes LRI much less frequently than HPIV-1 and HPIV-3, although the difference may be attributable to the difficulties with viral detection. Approximately 60% of HPIV-2 infections take place in the first 5 years of life;
the peak incidence occurs in the second year, but significant numbers of infants are infected under 1 year of age. Although ~requently overshadowed by HPIV-1 and HPIV-3, HPIV-2 can be predom,n~nt in some years (K. J. Henrickson, et al., "Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children," Clin. Infect. Dis.
18:770-779, 1994).
W O 97/16570 PCT~US96/17405 HPIV-3 is uni~ue among the parainfluenza viruses in its propensi~y to infect young infants less than 6 months of age.
LRI due to HPIV-3 causes approximately 20,000 infants and children to be hospitalized each year in the United States.
About 40% of HPIV-3 infections in the first 12 months of life lead to bronchiolitis and pneùmonia. It is second only to RSV
as a cause of LRI in neonates and young infants. Although endemic throughout the world, this virus also occurs in spring epidemics in North America.
Recent molecular analyses of all four serotypes has revealed more antigenic and genetic heterogeneity than had been appreciated previously (K. J. Henrickson, "Monoclonal antibodies to human parainfluen~a virus type 1 detect major antigenic changes in clinical isolates," J. Infect. Dis.
164:1128-1134, 1991; K. J. Henrickson, et al., "Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: Analysis of 12 clinical isolates," J. Infect. Dis. 166:995-1005, 1992; K. Prinoski, et al., "Evolution of the fusion protein gene of human parainfluenza virus 3," Virus Res. 22:55-69, 1992; M.
Tsurudome, et al., "Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies," Viroloqy 171:38-48, 1989; T. I. Yorlova, et al., " Studies of natural population variability of parainfluenza viruses during their epidemic circulation," Acta Virol.
25:64-70, 1991; K. L. van Wyke Coelingh, et al., "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Viroloqy 143:569-582, 1985; H.
Komada, et al., "Strain variation in parainfluenza virus type 4, J. Gen. Virol. 71:1581-1583, 1990; H. Komada, et al., 'IAntigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by monoclonal antibodies," J. Gen. Virol.
73:875-884, 1992). It appears that all four major HPIV types have virus subgroups that have unique antigenic and genetic characteristics. This includes variability even within HPIV-4 subtypes (H. Komada, et al., supra, 1990). The evolution of W O 97/16570 PCT~US96/1740 --4--these viruses appears to be similar in pattern to in~1uenza B.
Most HPIV strains have type-specific antigens that will react in polyclonal serologic testing as previously described.
However, HPIV-l and HPIV-3 have subgroups (A and B) showing progressive antigenic changes (K. J. Henrickson, suPra, 1991;
K. Prinoski, et al., suPra, 1992). Furthermore, HPIV-1 strains isolated over the past 10 years show persistent antigenic and genetic differences compared to the 1957 type strain (K. J. Henrickson, su~ra, 1991; K. J. Henrickson, supra, 1992; H. Komada, et al., su~ra, 1992). Because of this, standard reference sera prepared to HPIV isolates from the 1950s, or antigen prepared from these same "type" strains, may not react in current serologic assays.
Detection methods for human parainfluenza viruses 1, 2 and 3 currently include standard viral culture of the suspected infected fluid or tissue. This is a slow and expensive process that may take up to ten days to isolate the virus, and in the best hands, may have a sensitivity of only 40-50%. Direct antigen detection using immunofluorescence is also available both in this country and throughout the world, but the detection rate for HPIV by this method is highly variable with sensitivities averaging only in the 50-70~ range and specificities being in the 80-90% range.
A published method concerning the use of an RT-PCR ELISA
for the detection of a human parainfluenza virus type-3 was disclosed by Karron in the Journal of Clinical Microbioloqy (February, 1994, pp. 484-488) entitled "Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: Use of a reverse transcription-PCR-enzyme-immunoassay." The methods described in this paper are specific for an assay to detect human parainfluenza virus type 3 using specific sequences from the HN gene of HPIV-3. However, their methodology is different from the present invention because the present invention allows for the detection of HPIV-1, 2, and 3 in a single test. Furthermore, the present invention allows for the quantitation of HPIV genomic RNA in a clinical sample.
W O 97/16570 PCT~US96/17405 The published method concerning the use of an RT-PCR-ELISA for the detection of influenza A virus was disclosed by Thomas Cherian in the Journal of Clinical Microbiology (March, 1994, page 623-628) entitled "Use of P~R-enzyme immunoassay for identification of influenza A virus matrix RNA in clinical samples negative for cultivable virus." The methods described in this paper are specific for an assay to detect influenza A
virus using specific sequences from the matrix protein gene.
The Cherian method does not allow for the quantitation of influenza A and B virus genomic RNA in a clinical ~ample.
A published method concerning the use of an RT-PCR ELISA
for the detection of respiratory syncytial virus was disclosed by Freymuth in the Journal of Clinical Microbiology (December, 1995, page 3352-3355) entitled "Detection of respiratory syncytial virus by reverse tran~cription PCR and hybridization with a DNA enzyme immunoassay." The methods described in this paper are specific for an assay to detect RSV using specific sequences from the lB and N gene. This method does not allow for the detection of RSV, influenza virus, and HPIV in a single test or allow for the quantitation of RSV genomic RNA
in a clinical sample.
A fast and efficient method for detection and ~uantitation in a biological sample of human parainfluenza virus 1, 2 and 3 along with other disease-causing viruses, such as respiratory syncytial virus A and B and influenza virus A and B, is needed.
Summary of the Invention In one embodiment, the present invention is a method for evaluating a biological sample for the presence or absence of multiple viruses, including human parainfluenza virus, by use of an amplification reaction, such as the polymerase chain reaction. Preferably, this method comprises isolating RNA
from a biological sample and creating cDNA from the isolated RNA. The cDNA is exposed to oligonucleotide primers. If the assay is designed to detect human parainfluenza virus-l infection, the primer is selected from the group consisting of SEQ ID NOs:1-9. In this embodiment of the present invention, W O 97/16570 PCTrUS96/17405 one primer will be in the same 5' - 3' orientation presented in SEQ ID NOs:1-9 and the other primer will be in the inverse complement orientation. The exposure is under condltions in which the primers will amplify a human parainfluenza virus-1 sequence if the sequence is present. The sample is then examined to determined whether an amplification product exists. The presence of an amplification product indicates that the sample contained human parainfluenza virus-1.
The present invention additionally comprises exposing the cDNA to oligonucleotide primers designed to detect additional viruses. These viruses are selected from the group consisting of parainfluenza virus-2 and 3, respiratory syncytial virus A
and B, and influenza virus A and B. Preferred oligonucleotides designed to detect these additional viruses are described in Tables 5, 7 and 8. Preferably, SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58 are preferred primers for respiratory syncytial viruses A and B
and influenza viruses A and B. Tables 5, 7 and 8 also describe suitable probes designed to detect amplification products.
Preferably, SEQ ID NOs:32, 35, 38, 41, 44, 47, 50, 53, 56 and 59 are preferred probes for respiratory syncytial virus A and B
and influenza virus A and B.
The present invention is also a method for directly evaluating a biological sample for the presence or absence of human parainfluenza virus-1 infection along with infections caused by viruses selected from the group consisting of human parainfluenza virus-2 and 3, respiratory syncytial virus A and B, and influenza virus A and B. This method comprises the steps of isolating RNA from a biological sample. This RNA is then exposed to a probe selected from the group of SEQ ID
NOs:1-9 and complements of SEQ ID NOs:1-9 for detection of human parainfluenza virus-1. This exposure is under conditions that allow a hybridization reaction to occur if the probe is in the presence of a complementary nucleic acid.
The sample is then examined for the presence or absence of a hybridization product. The presence of a hybridization product indicates that the sample contains human parainfluenza virus-l nucleic acid and that the patient is infected with parainfluenza virus-l.
Oligonucleotide primers taken from Tables 5, 7 and 8 (as described above) can be used to examine the biological sample for the additional viruses.
In a preferred embodiment of the present invention, the amplification product described above is anchored onto a solid support, such as a microtiter plate, and detected via an enzyme-labeled probe. We have named this method of analyzing a PCR product "PCR-EHA" for PCR-enzyme hybridization assay.
The present invention is also a PCR-ELISA-based method of detecting human parainfluenze virus infection or multiple virus infection of a biological sample comprising the steps of isolating RNA from a biological sample, creating cDNA from the isolated RNA and exposing the cDNA to a primer pair specific for a human parainfluenza sequence and primers specific for respiratory syncytial virus A and B
Qequence or influenza A and B sequence under conditions permitting an amplification reaction. An amplification product will be formed if the sample contains the viruses.
The results of the amplification procedure are exposed to a protein-linked oligonucleotide probe, wherein the probe is of a sequence identical to a virus-specific sequence and wherein the protein-linked probe is attached to a solid support. One then determines whether the amplification product has hybridized to the oligonucleotide.
In another embodiment, the present invention is an improved method of PCR. In one embodiment, the method comprises the step of supplying primers to the reaction in non-equivalent concentrations. Preferable concentrations include an approximately 50 ~M:25 ~M ratio, 25 ~M:50 ~M ratio, 12.5 ~M:50 ~M ratio or 12.5 ~M:25 ~M ratio of 5' primer to 3' prlmer .
In another embodiment, the present invention is also an improved PCR reaction comprising the step of multiply denaturing the sample. Pre~erably, the sample is denatured at least twice for 5 minutes at 95~C.
It is an object of the present invention to detect human parainfluenza virus-1, 2 and 3, respiratory syncytial virus A
and B, and influenza virus A and B sequences in a single tube assay.
It is another object of the present invention to detect hemagglutinin neuraminidase sequences of HPIV-1, 2, or 3, influenza virus A matrix (M) gene sequences, influenza virus B
nonstructural (NS) gene sequences, RSV A lB, nucleocapsid and fusion (F) gene sequences, and RSV B lB, nucleocapsid, and attachment (G) gene sequences.
other objects, features and advantages of the present invention will become apparent after e~min~tion of the specification and claims.
DescriPtion of the Invention In General In one embodiment, the present invention is an assay for hllm~n parainfluenza-1 (HPIV-1). In another embodiment, this assay is combined in an assay for at least one other virus.
Preferably, this assay examines a biological sample for presence or absence of parainfluenza-1, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B.
In one aspect, the present invention involves performing an amplification reaction. Preferably, the amplification reaction is the PCR reaction. However, there are other suitable amplification techniques such as CPR (Cycling Probe Reaction), bDNA (Branched DNA Amplification), SSR (Self-Sustained Sequence Replication), SOA (Strand Displacement Amplification), QBR (Q-Beta Replicase), Re-AMP (Formerly RAMP), NASBA (Nucleic Acid Sequence Based Amplification), RCR
(Repair Chain Reaction), LCR (Ligase Chain Reaction), TAS
(Transorbtion Based Amplification System), and HCS (amplifies ribosomal RNA).
In one embodiment of the invention, this assay comprises the steps of exposing a cDNA created from RNA isolated from a biological sample to oligonucleotide primers chosen from the group described below in Tables 1, 5, 7 and 8. The sample may then be examined for the presence of an amplification product.
W ~ 97/16~70 PCTAUS96/17405 _g_ SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58 are preferable primers.
In another embodiment, the sequences in Tables 1, 5, 7 ~ and 8 may be used to design a probe which would be used to hybridize to nucleic acid sequenceS that are diagnostic for ~ the viruses. In a preferable embodiment, SEQ ID NOS: 32, 35, 38, 41, 44, 47, 50 53, 56 and 59 are preferable probes.
In another embodiment, the present invention is an assay for multiple viruses, preferably human parainfluenza virus-l, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B. This assay comprises the steps of exposing a CDNA created from RNA isolated from a biological sample to oligonucleotide primers specific for the viruses. This exposure is under conditions capable of amplifying a the virus-specific sequences if the sequences are pre~ent. The products of the PCR reaction are then exposed to a protein-linked oligonucleotide probe that has been attached to a solid support via the protein. One then determines whether the amplification product has bound to the solid support, preferably by use of enzymatic labels.
Kits In another embodiment, the present invention is a kit for assaying hllmAn parainfluenza virus type 1 and other viruses, preferably human parainfluenza virus-2 and -3, respiratory syncytial virus A and B and influenza virus A and B. In a preferred embodiment, the kit comprises a pair of primers selected from SEQ ID NOs:1-9. In another embodiment, the kit comprises at least one additional pair of primers designed to amplify respiratory syncytial virus A or B or influenza virus A or B. In a more preferred embodiment of the kit, the kit additionally comprises primers specific for human parainfluenza virus-2 and a pair of primers specific for human parainfluenza virus-3. In a most preferred embodiment of the kit, the kit additionally comprises primers selected from SEQ
ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58 specific for respiratory syncytial virus A and B and influenza virus A and B.
CA 02236022 l998-04-28 W O 97/16570 PCT~US96tl7405 In another em~odiment, the kit additionally comprises oligonucleotide probes specific for parainfluenza virus-l and probes specific for human parainfluenza virus-2 or 3, respiratory syncytial virus A or B, or influenza virus A or B.
In a more preferred embodiment, the kit additionally comprises probes selected from SEQ ID NOs:32, 35, 38, 41, 44, 47, 50 53, 56 and 59 specific for respiratory syncytial virus A and B and influenza virus A and B.
HPIV-1 Probes and Primers The present invention requires the use of a probe or primer pairs that are diagnostic for HPIV-1. To develop these probes or primers, one must first determine what genetic sequences are conserved between the many strains of HPIV-1.
If one were to use a sequence derived from only a few strains, one would risk not detecting an HPIV-1 strain that had mutated slightly from this group.
We had previously investigated genetic diversity in HPIV-1 by sequencing the hemagglutinin neuraminidase (HN) gene of 12 clinical isolates (Henrickson and Savatski, J. Infect. Dis.
166[5]:995-1005, 1992). HN is an important surface protein for this virus. Additionally, we were able to combine 13 HN
sequences obtained from G~nR~nk. (The Ge~R~nk location of the sequences we examined is listed in Appendix 1.) To this group, we added 15 isolates of HPIV-1 that we collected in 1991 during a single fall epidemic.
We compared these 15 new sequences to the known HPIV-1 sequences and looked for highly conserved nucleotide sequences. Our criteria was that the sequence should be greater than or e;3ual to 20 nucleotides in length and contain no nucleotide changes.
Table 1 describes the 9 highly conserved nucleotide sequence regions that we obtained. Table 2 describes the predicted amino acid sequences derived from the conserved nucleotide sequences in Table 1. (The bases and amino acid designations correspond to the numbering system for the HN
gene described in Henrickson and Savatski, J. Infect. Dis.
116[5]:995-1005, 1992).
CA 02236022 l998-04-28 WO 97/16S70 PCT~US96/17405 T~iBLE
HN base pair location: Sequence:
1. 342 - 361: 5~-ATATCAAGGACTATAAACAT (SEQ ID NO:1) 2. 528 - 548: 5'-1l~lG~AGATGTCCCGTAGGA (SEQ ID NO:2) 3. 640 - 673: 5'-TACCTTCATTATCAALla~l~ATGCAATATATGC (SEQ ID NO:3) 4. 675 - 705: 5'-TATTCATCAAACTTAATCACT~G~-ATGTG (SEQ ID NO:4) 5. 754 - 776: 5'-TAAATTCAGATATGTATCCTGAT (SEQ ID NO:5) 6. 798 - 822: 5'-ACCTATGACATCAACGACAACAGGA (SEQ ID NO:6) 0 7. 1173 - 1207: 5~-TGGcTAAAGAAAAGAcAA~ll~l~AAl~~ AAT (SEQ ID NO:7) 8. 1251 - 1276: 5'-GAGACTATTCCAATAACTCAAAATTA (SEQ ID NO:8) 9. 1734 - 1753: 5'-CCTAl~ll~llCAAGACAAG (SEQ ID NO:g) HN gene location: Sequence:
1. 96 aa-101 aa: 5'-ISRTIN (SEQ ID N0:10) 2. 158 aa-164 aa: 5'-FWRCPVG (SEQ ID N0:11) 3. 196 aa-205 aa: 5'-PSLSIGLAIY (SEQ ID N0:12) 4. 207 aa-216 aa: 5'-YSSNLITQGC (SEQ ID N0:13) 5. 234 aa-240 aa: 5'-NCDMYPD (SEQ ID N0:14) 6. 248 aa-255 aa: 5'-TYDINDNR (SEQ ID N0:15) 7. 373 aa-383 aa: 5'-WLKKRQVVNVL (SEQ ID N0:16) 8. 399 aa-406 aa: 5'-ETIPITQN (SEQ ID N0:17) 9. 560 aa-565 aa: 5'-PMLFKT (SEQ ID N0:1~) Therefore, to practice the present invention, one preferably uses a probe or primer pair derived from SEQ ID
NOs:1-9. The following criteria are useful in deriving such a probe or primer.
A. Probe A probe suitable to hybridize with a HN gene sequence will be at least 20 nucleotides in length. Preferably, a probe will be 30 nucleotides in length, and most preferably a probe will be at least 35 nucleotides in length. This length may be taken from any area of the sequence. The probe should preferably have a GC content of approximately 50%. SEQ ID
N0:1 is not a preferable probe because the GC composition is too low.
B. Primers To derive primers from the Table 1 sequences, one must first choose sequences that when amplified would produce a DNA
CA 02236022 l998-04-28 W O 97/16570 PCTnJS96/1740S
segment of sufficient length. For the PCR-ELISA technique that we described below in the Examples, one would need a DNA
segment of at least 100 nucleotides. If one wishes to visualize a PCR fragment on electrophoretic gel, a smaller fragment would suffice. However, for optimum PCR
amplification, a fragment of 100 nucleotides is still preferred. Preferably in both ca~es, the fragment ~hould exceed 150 nucleotides.
Additionally, the primer pair should be in an orientation that permits amplification. The forward primer should be in the 5' - 3' orientation depicted in Table 1. The reverse primer should be in an inverse complement orientation. The primers listed below in the Example (SEQ ID NOs:19 and 20) are examples of suitably oriented primers. One primer (SEQ ID
NO:19) is the 5' - 3' orientation of a portion of SEQ ID NO:2 depicted above. The other primer (SEQ ID NO:20) is the inverse complement orientation of a portion of SEQ ID NO:4.
Additionally, the primer should be chosen so that the two primers are not complementary at the 3' ends. This situation would lead to a hybridization reaction between the primers before the primers hybridize to the substrate material. A
complementary region of equal to or greater than 2 nucleotides will cause an unwanted primer hybridization. Preferably, there will be no complementary region at the 3' end.
Also preferred are primers that do not have internal complementary segments that allow formation of hairpins.
The primers should be at least 20 nucleotides in length.
This 20 nucleotides may be chosen from within the entire length of the sequence reported. For example, a 20 nucleotide length from SEQ ID NO:8 may start with the initial GAG or may start with the fifth nucleotide C. Primers may be longer than 20 nucleotides in length if one wishes.
As described above for probe selection, a GC percentage of approximately 50% is preferred. SEQ ID NO:1 is not a preferred primer because the GC concentration is too low.
The Example below describes a preferable method of isolating nucleic acid suitable to be amplified from a nasal wash. Briefly, the 1 - 2 ml specimens were emptied into CA 02236022 l998-04-28 W O 97/16570 PCT~US96/17405 transport tubes containing 2 ml of minimal essential medium supplemented with bovine serum albumin, amphotericin B, penicillin G, and gentamicin. These specimens are centrifuged - and the supernatants divided and refrigerated.
RNA is preferably isolated from these supernatant samples - by adding a guanidinium solution described below in the Examples. Other methods known in the art of isolating RNA
would also be suitable.
The following are preferred primer pairs for PCR
reactions. The numbers in Table 3 and 4 refer to the SEQ ID
NO. For example, "2" indicates SEQ ID NO:2.
GROUP A GROUP B GROUP C GROUP D GROUP E GROUP F GROUP G
2 + 3 3 + 5 4 + 5 5 + 7 6 + 7 7 + 8 8 + 9 2 + 4 3 + 6 4 + 6 5 + 8 6 + 8 7 + 9 2 + 5 3 + 7 4 + 7 5 + 9 6 + 9 2 + 6 3 + 8 4 + 8 2 + 7 3 + 9 4 + 9 2 + 8 2 + 9 HN-specific oligonucleotide primer pairs and probes that are preferred for PCR-EHA are listed below in Table 4.
Human Parainfluenza Probes and Primers for PCR-EHA-based Assay The present invention is also a PCR-EHA-based method of assaying a biological sample for any type human parainfluenza.
This assay depends on a protein-linked oligonucleotide specific for a human parainfluenza gene sequence linked to a solid support via the protein molecule.
The method begins with exposing a biological sample to a primer pair specific for any human parainfluenza gene. We have described above how to isolate a primer pair specific for the HN gene. The human parainfluenza genome is known to comprise a variety of genes and many of these would be CA 02236022 l998-04-28 .. ,~ ~
UJ ,,~ ~
,_ .~
~ CD ~D
Cl ~ <D
d~
p C~ ~ (D 1' co a~
.~ + + + +
O ~ ~ ~ ~ ~
+ + + + +
o ~
.t + + + + + +
c~ N N N N N N
-- W O 97/16570 PCTrUS96/17405 diagnostic for human parainfluenza. One would first obtain a nucleotide sequence of a human parainfluenza gene that is diagnostic for human parainfluenza as opposed to other infectious agents and cellular components. This could be facilitated by searching gene banks for any known sequence similar to the candidate sequence. If no matches are found, then the candidate sequence is likely to be specific to HPIV.
One would then construct a suitable primer pair from this gene sequence. Criteria listed above will be useful in constructing such a primer pair. One would then expose RNA
isolated from a suitable biological sample to this primer pair under conditions suitable for PCR amplification.
Separately, one would obtain a probe, using the criteria described above, specific for a human parainfluenza gene sequence. This probe should be attached to a protein molecule capable of binding a solid support. We have described above a procedure wherein BSA is attached to an oligonucleotide and used to bind a solid support. However, other protein molecules may be equally suitable. To determine whether a protein molecule is as suitable for the present invention as BSA, one would run a reaction with a candidate protein in parallel to a reaction with BSA and determine whether the candidate protein linked oligonucleotides attached to the plate with the same efficiency as the BSA-linked oligonucleotides.
The protein-linked oligonucleotide is then attached to a solid support in preparation for a PCR-EHA assay as described above. One then determines whether the amplification product i9 present, thus indicating that the biological sample is infected with human parainfluenza virus.
HPIV-l AssaY
To perform the method of the present invention, one must first select a probe and primer pair as described above and expose the cDNA described above to the primer pair.
After amplification, the PCR product is detected with the corresponding probe.
Bioloqical SamPle The probe or primers derived from the Table 1 conserved sequences are exposed to a biological sample that may contain HPIV-1 virus. This biological sample is preferably a nasal wash made from nasal secretions. Preferably, one would prepare the nasal wash by standard methods known to one of skill in the art. Preferably, as described in Henrickson, J.
Viol. Methods, 46:189-206, 1994 or Hall and Douglas, J.
Infect. Dis., 131:1-5, 1975.
However, other biological fluids such as nasal a~pirates or pleural fluid, preferably respiratory fluids, would also be suitable. Other body fluids such as blood or spinal fluid would all be suitable for the present invention.
The present invention is especially useful for the diagnosis of HPIV-l in immunocompromised children or adults.
These patients might preferably be diagnosed by broncho alveolar lavage.
Reverse Transcription Reaction Once RNA is isolated from the biological sample, one needs to perform a reverse transcription reaction to create a cDNA template for the primers.
A suitable reverse transcription reaction requires that the RNA sample be exposed to reverse transcriptase enzyme and deoxyribonucleotides so that a cDNA molecule may be created that corresponds to the initial RNA molecule.
Preferably, a reverse transcription reaction is performed as described below in the Examples.
A. PCR Reaction Preferably, one would choose to use a pair of primers and examine the final product for presence of a PCR amplification product. This e~Ami~tion could involve examining the products of the reaction on an electrophoretic gel and determining whether an amplified product of the appropriate size had been created. One of skill in the art of molecular biology will be aware of many protocols designed to optimize W O 97/16570 PCT~US96/17405 PCR reactions. Particularly useful protocols are described in PCR Protocols, Ed. M. Innis, et al. Academic Press, San Diego.
Most preferably, the PCR reaction will be coupled to an EHA procedure. As described below, one would anchor the PCR
amplification product to a solid support and ~mi ne the support for the presence of the PCR product. This procedure could be done in several ways. We will describe two of the most preferable ways below.
PCR-EHA Method A. In this method, one first attaches the amplified product to a solid support, such as a microtiter dish. For example, a streptavidin-coated plate may be provided. One of the selected primers may be attached to a biotin molecule so that an amplification product will be labelled with biotin and bind to the streptavidin plate.
The plate and product are then expo~ed to an HN-specific oligonucleotide probe containing a segment of the HN sequence.
This probe is attached to a marker enzyme, such as horseradish peroxidase (HRP), which may be detected via its enzymatic properties.
This protocol is described in detail in the Examples below.
PCR-EHA Method B. In PCR-EHA method B, one would attach a protein molecule capable of binding to the solid support, such as BSA, to an HN-specific oligonucleotide probe. The plate is coated with these protein-attached oligonucleotides that are available to hybridize with an amplified product. This amplified product is preferably attached to a label molecule, such as biotin, that is capable of being detected. In one embodiment, the biotin-labelled PCR product may be complexed to a streptavidin-horse radish peroxidase conjugate. One may then detect this complex with the appropriate substrate. A preferred method of performing this method is described below:
One must first derivitize the 5' phosphorylated oligonucleotide probe (oligolink derivitization reagent, PIERCE). Preferably, one would place 20 ug/ul of 5'-phosphorylated oligonucleotide in a clean 1.5 ul microcentrifuge tube. Remove 200 ul of the derivitization reagent and transfer to a vial containing EDC (ethyl-3[3-dimethyl-aminopropyl] carbodiamide).
Centrifuge the tube 3 seconds in a microcentrifuge to collect reactants in the bottom of the tube. Incubate the tube at 50~C for 30 minutes with constant mixing.
Resuspend the OligoLink~ matrix by vortexing until no solid is visible in the bottom of the tube. To an assembled spin column add 160 ul of matrix. Place the column in a microcentrifuge tube and centrifuge briefly (5 seconds) to remove the excess water. After spinning, carefully push the bottom cap onto the column. Discard the water from the collection tube.
Following the incubation period, add 81 Ul OligoLinkTM
binding buffer to the tube containing the derivitization oligonucleotide. Mix well and transfer the entire contents to the spin column containing the OligoLink~ matrix. Screw the top cap onto the spin column and invert the column to mix the reactants. Agitate the tightly capped spin column at room temperature for 15 minutes. Following the 15 minute incubation period, spin the column for 2 seconds with caps in place to collect the reactants in the bottom of the column.
Carefully remove top and bottom caps. Place the spin column in a collection tube and centrifuge for 10 seconds.
To the spin column add 500 ul OligoLink~ binding buffer.
Spin for 10 seconds. Wash the OligoLink~ matrix by adding 500 ul ethanol wash buffer. Spin 10 seconds. To spin the column and another 500 ul of ethanol wash buffer, followed by 1.0 ul of DTT solution. Replace the top cap on the spin column and invert several times to suspend the matrix in the reductant. Incubate 10 minutes with occasional mixing.
Following the reduction step, spin column 2 seconds with caps in place to collect reactants in the bottom of the column then remove top and bottom caps. Place spin column in a collection tube and spin for 10 seconds. Wash the excess DTT
from the column by adding 500 ul ethanol wash buffer. Spin 10 seconds.
Repeat the ethanol wash 3 more times using 500 ul of ethanol wash buffer each time. Add 160 ul H2O (preheated to 55~C), and incubate the entire column at 55~C for 5 minutes.
- Remove caps and place the column in a clean 1.5 ml collection tube. Spin the column for 20 seconds. Discard eluate.
One should then prepare a maleimide activated BSA/oligonucleotide probe complex (Imject Maleimide Activated Bovine Serum Albumin~, Pierce). Add 4 ml H2O to 2 mg activated BSA. Immediately mix the oligo and 0.2 ml BSA, incubate at room temperature for 2 hours and hold at -20~C.
To coat the ELISA plate, one may follow the following procedure. Preferably Costar, EIA/RIA plates, Medium Bind-in 3591, are obtained. Make up a solution containing 30 ul oligo-BSA complex in 15 ml coating buffer. (Coating buffer is 0.2M Carbonate-Bicarbonate buffer, pH 9.4). Add 100 ul/well of this solution and incubate at 4~C overnight. The next morning, empty plate and wash with PBS 3 times.
To block the ELISA plate, one would preferably use the following procedure: Add 300 ul/well blocking solution.
(Blocking solution is 5X Denhardt's solution, 1% gelatin tEIA
grade, BIORAD], 250 ug/ml herring sperm DNA.) Incubate overnight at 4~C. Remove blocking solution by aspiration next morning.
One then performs an enzyme hybridization assay.
Preferably, add 70 ul/well of premixed solution for solution hybridization. Mix 5 ul denatured PCR product (denature at 95~C, 5 minutes, keep on ice, 10 minutes) and 65 ul hybridization buffer. Incubate at 42~C 1 hour.
A preferable hybridization buffer is:
5X saline sodium phosphate EDTA
5X Denhardt's solution 1 pmol/100 ~l HRP-labeled HPIV-1 or HPIV-2, or HPIV-3 HN specific probe Wash 20 times with PBS at 37~C and 8 times with PBS
containing 0.05% Tween-20.
To analyze the reaction products, one would typically dilute strepavidin-HRP-conjugate 1:1000 with PBS containing 0.05% Tween-20. Add 200 ul/well and incubate at room W O 97/16570 PCTrUS96/17405 temperature for 30 minutes. Wash 5 times with PBS containing 0.5% Tween-20. Add 200 ul/well TMB-ELISA substrate buffer (Life Technologies) in the dark. Incubate at room temperature for 15 minutes with gentle agitation. Stop with 50 ul/well l.ON H2SO4. Incubate with gentle agitation for 5 minutes.
To interpret results, one may read optical density (OD) at 450 nM in 30 minutes. Samples with an O.D. greater than or equal to the mean of the negative control plus 3a of the negative control are considered positive. If the O.D. is less than this, the sample is considered negative.
To quantitate the copy nu~mber of HPIV-1 RNA in the sample, plot the EHA O.D. of the standard curve and fit each sample O.D. to this plot.
Quantification Standard The following method is useful in constructing a quantification standard: HPIV-1 virus RNA is synthesized from HPIV-1 virus genomic RNA by reverse transcription. The cDNA
is amplified with a primer pair of HNlB (ACT CTG GAC TCA AGA
ATG AGA AAT, SEQ ID NO:28) and HN2A (CAT ATT TGA CAA ATA GGC
AGG CAT, SEQ ID NO:29) to yield a 2070 bp HN gene product.
The PCR product and plasmid PCRTMII (Invitrogen, San Diego, CA) are ligated according to the supplier's protocol. A clone is obtained and named PCRTMII 2-1. This clone contains the 2070 bp HPIV-1 HN gene insert. The clone is, preferably, confirmed first by BamHI, XbaI, BamHI/XbaI digestion and then by sequencing with USB sequences PCR product sequencing kit (United States Biochemical, Cleveland). PCRTMII2-1 DNA is transcribed to RNA with SP6 RNA polymerase (Promega, Madison, WI). The RNA is e~m,n~d on denatured agarose gel, quantitated on a spectrophotometer to obtain copy number and frozen at -80~C. A known copy number of the transcript is introduced into virus genomic RNA lysis buffer and isolated with the same procedure as virus genomic RNA isolation when it is used as a quantitative standard.
Positive and negative controls which included transcript RNA from plasmid PCRTMII2-1 and PCRTMII are added at each assay. The cutoff value is calculated from the mean CA 02236022 l998-04-28 absorbance obtained from a group of seronegative samples plus three standard deviations. Copy number from subject samples are determined from the absorbances obtained ~rom a dilution - series of an RNA HN gene construct of know copy number described previously.
B. Probe HYbridization Reaction If one chooses to use a probe hybridization reaction as an HPIV-1 assay, one must expose the probe and viral genomic RNA under conditions known in the art to allow hybridization between the probe and HPIV-1 sequence. Preferable conditions are those described in the Examples for hybridization in the EHA reaction.
The sample is then examined for the presence of the hybridization product. Preferably, this e~m;n~tion would comprise labeling the probe and determining whether a double-stranded labelled product is present at the end of the assay procedure.
HPIV-1, 2 and 3 AssaY
If one wishes to assay for HPIV-1, 2 and 3, one could use the method of the present invention in combination with known sequences used as primers for HPIV-2 and 3. Table 5 below describes known HPIV-2 and 3 sequences. We have demonstrated that primers and probes from these known sequences are capable of amplifying and detecting HPIV-2 and 3 by RT-PCR-EHA.
HPIV-1 Assa~ Kit A kit to detect HPIV-1 would contain either a selected probe or selected PCR primers labelled as described below.
Additionally, substrate materials could be included, such as TMB if horseradish peroxidase is the enzyme label. A HN-specific oligonucleotide, preferably labelled, should beincluded.
HPIV-1, 2, and 3 RT-PCR-EHA Kit The present invention is also a kit for the detection of HPIV-1 or, alternatively, for the detection of HPIV-1, 2 and W O 97/16570 PCT~US96/17405 3. The kits are different depending on which of the three preferred PCR methods for detecting HPIV sequences one wishes to use:
PCR-EHA Method A
The kit for HPIV-1, 2 and 3 would comprise three pairs of primers for HPIV-1, HPIV-2 and HPIV-3 and three different probes specific for HPIV-l, HPIV-2 and HPIV-3. Preferable probes and primers are described in Table 5. The probes would all be enzymatically labelled. Preferable enzyme labels are also described in Table 5. Preferably, the kit also contains substrates for enzyme detection such as TMB (3',3',5',5 tetramethylbenzidine), bromocresol purple, and PNPP
(p-nitrophenylphosphate).
The procedure for using this kit would be as follows:
1. The three pairs of primers for HPIV-1, HPIV-2, and HPIV-3 are added in each of 3 tubes. A PCR reaction is then performed and PCR products are obtained.
2. The HPIV-1 probe, HPIV-2 probe and HPIV-3 probe are labeled with HRPO, alkaline phosphatase (AP) and urease, respectively.
3. One would then perform the EHA procedure described below in the Examples. One would preferably add 200 ~l/well TMB-ELISA substrate for HPIV-1 detection in one well, PNPP for HPIV-3 detection in another well and bromoresol purple for HPIV-2 detection in the third well.
PCR-EHA Method B
A different kit is necessary if one wishes to use PCR-EHA
method B. This kit, would provide three pairs of primers for HPIV-1, 2 and 3 and three HN-specific oligonucleotide probes for HPIV-1, 2 and 3. The oligonucleotides would all be attached to a protein molecule suitable for binding a solid support, such as BSA. One primer from each primer pair should be labelled enzymatically. The general procedure of PCR-EHA
Method B is as follows:
W O 97/16570 PCT~US96/17405 1. Three pairs of primers for HPIV-l, HPIV-2, and HPIV-3 are added in each PCR tube. A PCR reaction amplifies any HPIV-l, 2 or 3 sequences.
- 2. BSA/HPIV-l oligonucleotide complex, BSA/~PIV-2 oligonucleotide complex, and BSA/HPIV-3 oligonucleotide complex are coated on microtiter plates separately.
3. The products of step 1 are combined with the labelled probes and hybridization products are detected. The PCR-EHA procedure B is described above.
Alternatively, one may wish to use PCR-EHA method B with probes that are not specific for the HN protein. A suitable kit for this method would provide at least one pair of primers specific for human parainfluenza virus genome and one protein-linked oligonucleotide probe specific for the hllm~n parainfluenza virus amplification product. As above, one primer from the primer pair should be enzymatically labelled.
The general procedure of PCR-EHA method B, as described above, would then be followed. Preferably, one would provide three pairs of primers and three probes specific for sequences found in human parainfluenza-1, 2 and 3 in the kit.
PCR Method C
The third PCR method is simply a PCR reaction and visualization of the PCR product. For the third PCR method, one would simply need to provide three pairs of primers for ~IPIV-1, 2 and 3. After the amplification reaction the PCR
products would be examined on a electrophoretic gel, preferably a 2~ agarose gel, and visualized. This visualization is preferably via ethidium bromide staining.
If the primers and probes described in Table 5 are used, the PCR product size for HPIV-l is 180, for HPIV-2 is 244, and for HPIV-3 is 278 bp or 151 bp, respectively. The density of the band is examined by densitometry and compared with a standard.
We have successfully used the kit described above to assay biological samples for human parainfluenza virus-1, 2 and 3.
W O 97/16~70 PCTAUS96/17405 T~iBLE 5 PRIMERS AND PROBES USEDIN HPIV-1,HPIV-2,HPIV-3PCR-EHA KIT
S~PCR ENZYME
SUBTYPE SF~IIE' PRODUCT I ~R~I IIG SUBSTRATE
HPIV-1 5' Primer: ATT,TCT,GGA,GAT,GTC,CCG, TAG,GAG,AAC (SEQ ID NO:19) 180 3' Primer: Bio~n-CAC,ATC,CTT,GAG,TGA, TTA,AGT,TTG,ATG,A (SEQ ID NO:20) Probe: TAC,CTT,CAT,TAT,CAA,TTG,GTG, ATG,CAA,TAT,ATG (SEQ ID NO:21) HRPO TMB
HPIV-2 5' Primer: GTC,TCA,TGG,ATT,CCG,ATG, ATT,CAC,AGC,AA (SEQ ID NO:22) 244 3' Primer: GAT,GTA,CGC,TGC,ATC,ATG, CAG,AAG,CAG,A (SEQ ID NO:23) Probe: AGG,ATA,TGC,ATA,CTG,GGA,GCA, Blull~ ~:~dl TGT,CCA,ACA,CCA (SEQ ID NO:24) Urease Purple HPIV-3 5' Primer: TAT,GGA,CAA,TAA,TCC,TGG, TGT,TAT,TAT,C(SEQ ID NO:25) 278 3' Primer: TAA, m, CAC,TAA,TGA,ATT,TCC, TM,GAT,C(SEQ ID NO:26) 5' Primer: AAG,ATC,CAA,ATG,GCA,TCG, 151 GAT,AAT,A (SEQ ID NO:64) 3' Primer: TAA,TTT,CAC,TAA,TGA,ATT,TCC, TAA,GAT,C(SEQ ID NO:65) Probe: GTG,AAT,ACA,AGG,~;TT,CTT,ACA, ATT,CAG,AGT,CAT (SEQ ID NO:27) AP PNPP
Probes and Primers for Res~iratorY SYncYtial Virus A and B and Influenza Virus A and B
The present invention requires that the biological sample be examined for the presence of at least one virus selected from the group of respiratory syncytial virus A and B and influenza virus A and B. The Examples below demonstrate suitable primers and probes in Tables 7 and 8.
Preferably, primers will be selected from SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58. Preferably, probes will be selected from SEQ ID NOs:32, 35, 38, 41, 44, 47, 50, 53, 56 and 59.
The multiple virus assay would be performed identically to the assays described above except that multiple primers or probes will be included in the assay mix.
CA 02236022 l998-04-28 W O 97/16570 PCT~US96/17405 MISMATCHED PRIMERS AND MULTIPLE DENATURATION IMPROVE THE
DETECTION OF HUMAN PARAINFLUENZA VIRUS BY QUANTITATIVE REVERSE
TRANSCRIPTION-PCR-ENZYME HYBRIDIZATION ASSAY.
The final step in reverse transcription-PCR-enzyme hybridization assay (RT-PCR-EHA) is the enzymatic modification of a colourless substrate solution to a colored one. The optical density (OD) of this color change is measured on a spectrophotometer and represents the outcome of the EHA
portion of the RT-PCR-EHA assay. Increasing the OD of positive samples in comparison to negative and control samples would result in increased sensitivity and specificity of the RT-PCR-EHA.
As described below in the Examples, we have developed two methods to increase the optical density of EHA. In comparison with conventional methods using matched PCR primers or conventional PCR product denaturation, the optical density i5 increased 3.6 times by using mismatched PCR primer concentration and 6.1 times by using multiple denaturation of the PCR products. Our data demonstrates that mismatched PCR
primer concentration and multiple denaturation of the PCR
products significantly increase the optical density of EHA
positive samples without increasing the background. The two methods will greatly benefit the application of RT-PCR-EHA and any PCR based diagnostic test including the diagnosis of infectious diseases, cancer, genetic disease, metabolic disorders, etc.
Therefore, the present invention is also an improved method of PCR. The method comprises the step of supplying mismatched primer concentration to a PCR reaction. For example, one of the Examples below demonstrates the efficacy of mismatched primer concentrations where the 5' to 3' primer ratio is 50 ~M:25 ~M, 25 ~M:50 ~M, 12.5 ~M:50 ~M and 12.S
~M:25 ~M. By "approximately" we mean that the ratio is within 10% of the given ratio.
The present invention is also an improved method of PCR
comprising the step o~ denaturing the initial reaction mixture at least twice, preferably at 95~C for 5 minutes for each W O 97/16570 PCT~US96/17405 denaturation. In a most preferable version of the reaction, the sample is denatured at least 4 times.
Exam~les ExamPle 1. Detection and Ouantification of HPIV-1 HN Gene Am~lification Products bY a NonisotoPic Svstem: RT-PCR-EHA.
The following describes our procedure for assaying nasal wash samples for HPIV-1:
A. Collection of nasal wash sPecimens.
Standard nasal washes were carried out on patients suspected of having a parainfluenza virus infection.
The specimens averaged 1-2 ml and were immediately emptied into transport tubes containing 2 ml of minimum essential medium (MEM) supplemented with 0.5% bovine serum albumin, gentamicin (5 ~g/ml).
Transport tubes were kept at room temperature 0.5-3 hours in the emergency room before being refrigerated at 4~C.
The specimens were centrifuged at 2000 x g for 15 minutes, and the supernatants were then divided. 0.5-1 ml aliquots were refrigerated at 4~C, until frozen at -80~C later that day.
B. Construction of the auantitation standard.
The quantitation standard was a 2070-base RNA transcript of a plasmid designated PCRTMII2-1. To construct this standard, HPIV-l virus RNA was synthesized from HPIV-1 virus genomic RNA by reverse transcription. The cDNA was amplified with a primer pair of HNlB (ACT CTG GAC TCA AGA ATG AGA AAT, SEQ ID NO:28) and HN2A (CAT ATT TGA CAA ATA GGC AGG CAT, SEQ
ID NO:29) to yield a 2070 bp HN gene product.
The PCR product and plasmid PCRTMII (InVitrogen, San Diego, CA) were ligated under standard conditions.
Transformation of INVaF'-competent cells (InVitrogen, San Diego, CA) with the ligated plasmid was carried out according to the suppliers protocol. A clone was obtained and named PCRIMII2-1. This clone contained the 2070 bp HPIV-1 HA gene insert.
CA 02236022 l998-04-28 W O 97/l6570 PCTAUS96/17405 The clone was checked first by BamHI, XbaI, BamHI/XbaI
digestion and then by sequencing with USB sequenase PCR
product sequencing kit (United States Biochemical, Cleveland).
PCRTMII2-1 DNA was transcribed to RNA with SP6 RNA
polymerase tPromega, Madison, WI). The RNA was viewed on a denatured agarose gel, quantitated on a spectrophotometer to obtain correct copy number, and frozen at -70~C.
C. RNA Isolation Into a sterile 1.5 ml microfuge tube, 0.5 ml guanidinium solution was added to 100-200 ul tissue culture supernatant or the clinical nasal wash described above. The guanidinium solution was:
Guanidinium (iso)thiocyanate 4 M
Sodium Citrate, pH 7 25 mM
Sarcosyl 2% (w/v) 2-mercaptoethanol 0.1 M
The samples were homogenized by vortexing. 50 ~1 (1/10 volume) of 2M sodium acetate pH 4 was added. 500 ~1 (1 volume) water saturated phenol (pre-warmed) was added. 100 ~1 (1/5 volume) chloroform isoamyl alcohol (49:1) was added.
The mixed solution was vortexed thoroughly and then cooled on ice 5 minutes. The suspension was centrifuged in a microfuge at full speed for 15 minutes at 4~C. The RNA was present in the top aqueous phase whereas DNA and proteins were in the interphase and phenolic phases. The aqueous phase was transferred to a microfuge tube and 500 ~1 (1 volume) isopropanol was added. The samples were stored at -70~C for at least 60 minutes and then spun at 4~C for 15 minutes. RNA
precipitated and formed a white-yellow pellet at the bottom of the tube. The supernatant was removed and the RNA pellet was washed twice with 70% ethanol in DEPC H20. DEPC H20 iS 0.196 Diethylpyrocarbonate in water, shaken well, incubated 2 hours 37~C, and autoclaved.
The RNA pellet was vacuum dried briefly for 10-15 minutes and then dissolved by vortexing in 50 ~l DEPC H2O containing O.5 ,ul RNase inhibitor (Boehringer Mannheim, 50 units/ml).
The RNA was stored at -20~C or -70~C.
CA 02236022 l998-04-28 D. Reverse TranscriPtion (RT) Reaction A RT master mix was prepared:
RT Master MixVolume (~l)Final Cone~ntration 25 mM MgCl2 4 ~l 5 mM
lOX PCR buffer (PEC) 2 lX
dGTP 2 1 mM
dATP 2 1 mM
dTTP 2 1 mM
0 dCTP 2 1 mM
RNase in-h-ibitor (20 units/ml) 1 1 u/~l MULV reverse transcriptase 1 2.5 u/~l Random h~Am~rs l 2.5 u/~1 18 ~l/sample 18 ~1l RT master mix was added to a thermalcycling tube.
2 ~1 RNA from the sample described above was added. 2 ~1 quantitation standard RNA with 10, 50, lO0, lOOO, 5000, lO,OOO
copies respectively, were added and kept at room temperature for 10 minutes. The samples were incubated 42~C for 60 minutes, then 99~C for 5 minutes, then held at 5~C.\
E. PCR AmPlification A PCR master mix was prepared:
PCR master mix Volume (~l) Final Concentrations 25 mM MgCl, 2 ~l 2 mM
lOX PCR buffer 4 lX
sterile distilled H2O 31.5 37.5 ~l/sample PCR sample tubes were prepared:
PCR master mix 37.5 ~l -Upstream primer PF526 l l.0 ~M
Downstream primer PR678 biotin 1 1.0 ~M
cDNA lO
Ampli Taq DNA polymerase 0.5 2.5 units/50 ~1 50 ~1 W ~ 97/16570 PCTAUS96/17405 The samples were overlayed with 40 ~1 mineral oil. The tubes were placed in a 70~C prewarmed thermal cycler within 2 minutes of adding Ampli Taq to reduce nonspecific binding of primers and production of nonspecific products. Hot start is optional (see Ampli Taq directions).
Sequence of primer PF 526: ATT TCT GGA GAT GTC CCG TAG
GAG AAC (SEQ ID NO:l9).
Sequence of primer PR 678: Biotin-CAC ATC CTT GAG TGA
TTA AGT TTG ATG AT (SEQ ID NO:20).
The thermalcycling program was as follows:
1. 95~C, 2 minutes (1 cycle) 2. 95~C, 1 minute; 55~C, 45 seconds; 72~C, 45 seconds, (2 cycles) 3. 94~C, 1 minute; 60~C, 45 seconds; 72~C, 45 seconds, (28 cycles) 4. 72~C, 7 minutes (final extension) F. Denature PCR Product To denature the DNA, the samples were incubated at 95~C
for 5 minutes and then kept on ice.
G. EHA
300 ~l/well blocking solution was added to Reacti-Bind Strepavidin Coated Polystyrene Strep Plates (Pierce Catalog #15120) and incubated overnight at 4~C. The blocking solution was removed by aspiration.
Blocking solution:
5X Denhardt's solution 1% gelatin (EIA grade, BIOR~D) 250 ~g/ml herring sperm DNA (Promega) 70 ~l/well of premixed solution was added for solution hybridization. 5 ~1 denatured PCR product was mixed with 65 ~l hybridization buffer and incubated 42~C, 1 hour.
Hybridization buffer:
5X saline sodium phosphate EDTA
5X Denhardt's solution 1 pmol/100 ~l HRP-labeled HPIV-l HN specific probe The sequence of HRP-labeled HPIV-1 HN specific probe was HRP-TAC, CTT, CAT, TAT, CAA, TTG, GTG, ATG, CAA, TAT, ATG (SEQ
ID NO:21). The sample was washed 20 times with lX PBS 0.05 Tween-20. 200 ~l/well TMB-EHA substrate (Life Technologies Catalog #15980-014) was added, and the sample was incubated 15 minutes 20~C in the dark. The reaction was stopped by adding 50 ~l/well lN H2SO4. The O.D. of the sample was measured at 450 nm.
H. InterPretation of re~ults Samples with O.D.'s greater than or equal to the mean of the negative control plus at least 3 times ~ of the negative control and greater than 0.100 O.D. are considered positive.
If the O.D. is less than this, it is considered negative.
To quantitate the copy number of HPIV-1 RNA in the original sample, the EHA O.D. of the standard curve was compared and the copy number with each sample was read. Table 6, below, discloses data obtained in the Example described above. Nasal samples were independently cultured and identified. Both positive and negative samples were analyzed according to the present invention.
RT-PCR-EHA
Mean of HPIV
Specimen Group No. Specimens No. Positive No. Negative copy/mL
virus culture pogitive 9 9 0 239607 virug culture negative 40 4 36 36528 The 4 positive samples from the virus culture negative samples were found to have a mean HPIV copy/ml of 36528 transcripts. The other negative samples had no copies of HPIV
transcripts.
W O 97/16570 PCT~US96/17405 ExamPle 2. Preparation of Primers and Probes for use in Virus AssaY for Influenza A and B and RespiratorY SYncYtial Virus A
and B.
Tables 7 and 8 describe primers and probes that we have successfully used in individual assays for influenza A and B
virus detection and respiratory syncytial virus A and B
detection by quantitative RT-PCR-EHA.
The probes and primers were prepared as follows:
Sequences from Genbank and published sources were ~m;n~d (see Appendix 2) and appropriate probes and primers were developed (see Tables 7 and 8). Individual assays were performed as described above for HPIV with the same criteria for success. The results of the RT-PCR-EHA for RSV-A, B and influenza A and B are similar to those found for HPIV-l, 2 and 3. All primers and probes listed in Tables 7 and 8 were successful. (The numbering referred to in Tables 7 and 8 for "position of sequence" begins at the 5' end of the gene.) Example 3. Diaqnosis of Human Parainfluenza Virus Type 1, Type 2, Type 3, Respiratory SyncYtial Virus A and B, and Influenza Virus A and B Infection bY RT-PCR-EHA Usinq Mixed Primers in a Sinqle Tube Multiplex Assay.
Here, we describe an RT-PCR-EHA for the detection of hllm~n parainfluenza virus type 1 (HPIV-1), type 2 (HPIV-2), type 3 (HPIV-3), respiratory syncytial virus type A (RSV-A), type B (RSV-B), influenza virus A and B RNA with mixed primers in a single tube assay. In comparison with separated RT-PCR-EHA, the single tube multiplex EHA-RT-PCR demonstrated the same sensitivity and specificity. This method will represent an important tool for the timely and sensitive diagnosis of HPIV-1, HPIV-2, HPIV-3, RSV-A, RSV-B, influenza virus A and B
virus infections.
~ '' g ~q o P.~
s ~ ~ ", ~ ~ ~ o~ o ~ ~ o r-- ~ oo ~ ~ oO 1~ 00 E
t t t ~ ~ D t c t ~- t ~- t- ' c t ' C ~ C c C~ C c . Y, -- . a t ~ ~ . ~ t . ' d r ' ~ ' V C~ ~ ¢ ' ~ ' V E-' ~s~ c~s~ ~'b~ ~s~ c'- ~ c'- ~
o o e~ .o O ~ .0 o ~ .o o E- . O E- . O
m ~ ~ ¢ ~ ~ ¢ ~ P~
~ ~ ~ ~ ,o ~ ~ ~o ~ ~ ~~ ~ ~ 2 ~ ~ ~~
t_ ~ ~ ~V et ~ 1~ ~~ ~ ~~ ~ ~ ~ ~ ~ ~
o ~ ~ rq r~ r~ r" r"
¢ ~ ¢ ¢ ¢ Z Z Z Z Z Z
Zo ~
W O 97/16570 PCTrUS96/17405 ~ ~ Z
g ~_ ~Z ~ ~
~ ~ o~ ~ o -- ~ ~ C~ _ ~ o~ ~, --z ~ ~ D X ~ ~r X ~ X Y .Y ,=
p~ ~ G o ~ ~ O G ~ 2 ~'" 4 ~Z ~ ~ ~ Z ~
A. Materials and Methods Virus stocks. HPIV-1 (HA-2, strain C39; American Type Culture Collection, Rockville, Maryland, USA), HPIV-2 (LRS-76 clinical isolate, 1991, Milwaukee), HPIV-3 (LRS-75 clinical 5 isolate, 1991, Milwaukee), RSV-A (A2 strain; American Type Culture Collection), RSV-B (RSV; strain 9320; American Type Culture Collection), influenza virus A (LRS-147 clinical isolate, 1991, Milwaukee), influenza virus B (Jones strain;
American Type Culture Collection) were used and prepared in 10 our laboratory by standard protocols.
Viral qenomic RNA isolation. Viral genomic RNA was extracted from frozen nasal wash specimens by previously described methods. Briefly, samples were treated with guanidinium-isothiocyanate (4 M) in sodium citrate (25 mM) 15 buffer (pH 7.0) with 0.5% sarcoryl and 0.1 M ~-mercaptoethanol; 0.1 volume of 2 M sodium acetate was added together with 1 volume of water-saturated phenol and 0.2 volume of chloroform-isoamyl alcohol (49:1). After centrifugation, RNA was extracted in the a~ueous phase, and 20 the phenol-chloroform extraction was repeated once more. The RNA was then precipitated with isopropanol at -20~C for 1 hour. After centrifugation, the pellet was washed twice with 70% ethanol and was dissolved in 50 ~1 of diethyl pyrocarbonate-treated water containing 20 U of RNase 25 inhibitor.
cDNA sYnthesis. cDNA was synthesized from random hexamers by incubation with murine leukemia virus (MuLV) reverse transcriptase (Perkin-Elmer Cetus, Norwalk, Connecticut USA) and 1 mM each deoxynucleoside triphosphates 30 at 42~C for 60 minutes and 99~C for 5 minutes and was soaked at 5~C for 5 minutesFifteen nanograms each of viral RNA from virus stock was used for a single test.
Amplification of cDNA bY PCR. For PCR amplification, 6 1/2 pairs of primers (RSV A and B share a 3' primer) from 35 highly conserved sequences of the HPIV-1, 2, and 3 HN genes, the lB and N genes from RSV-A and B and the M gene from influenza virus A and NS gene from influenza B were used for amplification.
W O 97/16570 PCT~US96/17~05 The primers for the HPIV-l HN gene are HPIV-1 PF 526 (SEQ
ID NO:19) and HPIV-1 PR 678 (SEQ ID NO:20); for HPIV-2 HN gene were HPIV-2 PF 301 (SEQ ID NO:22) and HPIV-2 PR 545 (SEQ ID
NO:23), for HPIV-3 HN gene were HPIV-3 PF 321 (SEQ ID NO:25), 5 and HPIV-3 PR 471 (SEQ ID NO:26).
~ For the RSVA IB and N gene we used RSVlB 967 (SEQ ID
NO:48) and RSVAN1136 (SEQ ID NO:49), for RSVB lB and N gene we used primers RSVB960 (SEQ ID NO:54) and RSVAN1136 (SEQ ID
NO:43), for influenza virus A M gene we used primers INFAM32 (SEQ ID NO:30) and INFAM243 (SEQ ID NO:34), and for influenza virus B NS gene we used primers INFBNS748 (SEQ ID NO:45) and INFBNS967 (SEQ ID NO:46).
The assay mixture contained 10 mM Tris-HCl, 2 mM MgCl2, O.2 mM (each) deoxynucleoside triphosphates, O.2 ~M (each) 15 primers, and 2.5 U of AmpliTaq DNA polymerase (Perkin-Elmer Cetus). After denaturation at 95~C for 2 minutes, aliquots were then amplified by two cycles at 95~C for 1 minute, 55~C
for 45 seconds, and 72~C for 45 seconds and 29 cycles of 95~C
for 1 minute, 60~C for 45 seconds, and 72~C for 45 seconds and 20 were then held at 72~C for 7 minutes.
The PCR products were analyzed by electrophoresis on a 2%
agarose gel in TBE (Tris-borate-EDTA) buffer at 80 V for 1 hour and 15 minutes and were stained with ethidium bromide.
The PCR products were also analyzed using liquid enzyme 25 hybridization (EHA).
B. Results The PCR products were analyzed by electrophoresis on 2%
agarose gel. The seven PCR products for HPIV-l, HPIV-2, HPIV-30 3, RSV-A, RSV-B, influenza virus A and influenza virus B were 180 bp, 245 bp, 151 bp, 189 bp, 196 bp, 227 bp, and 244 bp.
Only a specific band showed up in response to each set of primers. In comparison with RT-PCR with one pair of primers, the band obtained from RT-PCR with mixed prlmers in single 35 tube reaction showed the same size and the same sensitivity.
The results obtained in our experiments demonstrate the possibility for rapid diagnosis of HPIV-1, HPIV-2, HPIV-3, RSV-A, RSV-B, influenza virus A, and influenza virus B
W O 97/16570 PCTrUS96/17405 infections by RT-PCR with mixed primers in single tube reaction.
The PCR product from all seven viruses was also detected using specific probes (SEQ ID NOs:21, 24, 27, 50, 56, 32 and 5 47) to each virus in EHA.
Example 4. Mismatched PCR Primer Concentration Improves the Det~ction of HPIV-1, 2, or 3 bY Ouantitative RT-PCR-EHA.
In the Example below, we demonstrate that varying the 10 ratio of primer concentration drastically improves PCR
performance.
A. Materia~s and Methods Construction of the auantitation standard. To construct 15 a standard, HPIV-1, 2, or 3 virus cDNA was synthesized from HPIV-1, 2, or 3 virus genomic RNA by reverse transcription.
The cDNA was amplified using the primer pairs (e.g., HPIV3 5'0013 ~AGG, AGT, A~A, GTT, ACG, CAA, T (SEQ ID NO:60)) and HPIV-3 3'1957 (TGA, TTA, CTT, ATC, ATA, TAC, TTG (SEQ ID
20 N0:61)) to yield a 1945 bp HPIV-3 HN gene product). The PCR
product and plasmid PCR~II (Invitrogen, San Diego, CA) were ligated under standard conditions. Transformation of INVaF'-competent cells (Invitrogen, San Diego, CA) with the ligated plasmid was carried out according to the supplier's protocol.
25 PCR~II HPIV-1, 2 or 3 HN DNA was transcribed to RNA with SP6 RNA polymerase (Promega, Madison, WI). The RNA was examined on a denatured Agarose gel, ~uantitated on a spectrophotometer to obtain the copy number and frozen at -70~C.
cDNA svnthesis. cDNA was synthesized from random 30 hexamers by incubation at 42~C for 60 minutes, 99~C for 5 minutes, and soaked at 5~C for 5 minutes with MuLV reverse transcriptase (Perkin-Elmer Cetus, Norwalk, CT) and 1 mM dNTP.
Fifteen nanograms of virus RNA from virus stocks was used for a single test.
Amplification of cDNA bY PCR. For PCR amplification, primers from highly conserved sequences of the HPIV-1, 2, or 3 HN gene (e.g., PF 321-AAG, ATC, CAA, ATG, GCA, TCG, GAT, AAT, A, SEQ ID NO:62, from bp 321 to 345 sense), and PR 471- TAA, TTT, CAC, TAA, TGA, ATT, TCC, TAA, GAT, C, SEQ ID NO:63, from bp 443 to 471, antisense) were used for amplification. HPIV-1, 2, or 3 primers (e.g., PR 471) were biotinylated at the 5' end (Operon, Alameda, CA). To optimize the PCR primer 5 concentration, 11 pairs of different primer concentrations ~ were tested in RT-PCR-EHA using HPIV-1, 2, or 3 specific primer pairs (Table 9). The PCR mixture contained 10 mM Tris, 2 mM MgCl, 0.2 mM dNTP, and 2.5 U Ampli Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT). After denaturation at 95~C
10 2 minutes, aliquots were then amplified by two cycles of 95~C
for 1 minute, 55~C for 45 seconds, 72~C for 45 seconds, 34 cycles at 95~C for 1 minute, 60~C for 45 seconds, 72~C for 45 seconds, and hold at 72~C for 7 minutes. After final extension at 72~C for 7 minutes, PCR products were denatured 15 by heating at 95~C for 5 minutes and then kept on ice (standard conditions). To optimize the effect of heat denaturation on the RT-PCR-EHA, PCR products were denatured by using different heating conditions and then kept on ice (Table 10). Positive and negative controls which included transcript 20 RNA from plasmid PCR~ HPIV-1, 2, or 3 HM and PCR~II were added to each assay.
The PCR products were analyzed by electrophoresis on 2~
agarose gel in TBE buffer, 80 volts for 1 hour 15 minutes, and stained with ethidium bromide.
Detection and quantitation of PCR product by enzYme-hybridization assaY (EHA). To detect and quantitate the PCR
products, 96-well microplates were coated with streptavidin.
Wells were then filled with 300 ~l of a blocking solution containing 5x Denhardt's solution, 1% gelatin, 250 ~g/ml 30 sheared herring sperm DNA (Promega, Madison, WI) at 4~C.
Immediately before use, the blocking solution was aspirated from each well and 5 ~l of the previously made PCR products and 65 ~l of a hybridization solution containing 5x saline sodium phosphate EDTA, 5x Denhardt's solution, and 1 pmol/100 35 ~l of HRP-labeled HPIV 1, 2, or 3 specific probe (e.g., HPIV-3 HN probe 369-GTG, AAT, ACA, AGG, CTT, CTT, ACA, ATT, CAG, AGT, CAT, SEQ ID NO:27, from 369 to 401, sense) were added to individual wells. A capture and hybridization reaction was then carried out in the well for 1 hour at 42~C. The 96-well microplate was washed with PBS cont~n~n~ 0.05% Tween-20. 200 ~1 of substrate solution TMB-ELISA, (Life Technologies), was added to each well. After 15 minutes the reaction wa~ stopped with 1 N H2SO4 and the optical density of each well was measured at 450 nm on a spectrophotometer (Biotek, EL3~.
Results and Discussion Table 9 tabulates the results o~ varying primer concentration:
OPTlMeATlON OF PCR PRIMER CONCENTRATION IN RT-PCR-EHA
PCR Primer 1 2 3 4 5 6 7 8 9 10 11 PF321, 5'Primer~ 50 25 12.5 6.25 50 50 50 25 12.5 6.25 12.5 PR471,3'Primert 50 25 12.5 6.25 25 12.5 6.25 50 50 50 25 15 ~ 'Ir~
Optcal Densityt 0.2 0.257 0.026 0.021 0.455 0.047 0.012 0.38 0.652 0.244 0.71 Primer wu~.~ in ~uM.
I spccific primers at450 ~a~ ' _ (A450).
tHPlV-3 specific primers.
In comparison with conventional matched PCR primers (50 ~M each), mismatched PCR primer concentration (5' primer PF
321 at concentration 12.5 ~M, and biotinylated 3' primer PR471, at concentration 25 ~M) showed a 3.59 times increase in optical density. Mismatched primer concentration may create more biotin-labeled PCR product which will be captured by the streptavidin coated plate and thereby increase the value o~
optical density reading.
MULTIPLE DENATURATION OF THE PCR PRODUCT IMPROVES THE
DETECTION OF HPIV-1, 2, OR 3 BY QUANTITATIVE RT-PCR-EHA.
DENATURE CONDmON
Denature TL~ ., 95~C, 5' 95~C, 10' 95~C, 95~C, 95~C, 95~C, 5' 95~C, 5' (~C) and time (min) 1S 20' S
Time Kept on icc (min) 10' 10' 10' 10' 10' 10~ 10 35 Time(s) x1 x1 x1 x1 x2 x3 x4 Value of optical densi~ 0.185 0.145 0.162 0.182 0.561 0.584 1.126 SU~ ITE SHEET (RULE 26) In comparison with the conventional heat denaturation method (#1, Table 10) the optical density using the double denaturation method (#5, Table 10) increased 3.03 times and the four time denaturation method (#7, Table 10) showed a 6.05 5 times higher OD. However, lengthening the denaturation time did not increase the optical density. Multiply denatured PCR
product demonstrated more single-stranded DNA on agarose gel.
This would allow more binding of viral-specific probes (also single-stranded) during the EHA portion of the RT-PCR-EHA.
Increased probe binding would then lead directly to increased OD in the test well.
_ CA 02236022 l998-04-28 - W 097/16570 PCT~US96/17405 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Henrickson, Kelly J.
Fan, Jiang (n.m.i.) (ii) TITLE OF INVENTION: VIRUS ASSAY METHOD
(iii) NUMBER OF SEQUENCES: 65 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Quarles & Brady (B) STREET: 411 East Wisconsin Avenue (C) CITY: Milwaukee (D) STATE: Wisconsin (E) COUNTRY: U.S.A.
(F) ZIP: 53202-4497 (v) COM~Ul'~K READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COM~Ul~: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1. 25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Baker, Jean C.
(B) REGISTRATION NUMBER: 35,433 (C) REFERENCE/DOCKET NUMBER: 650053.91037 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (414) 277-5000 (B) TELEFAX: (414) 271-3552 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ~ (D) TOPOLOGY: 1 inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOhOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
- W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Ile Ser Arg Thr Ile Asn (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Phe Trp Arg Cys Pro Val Gly (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Pro Ser Leu Ser Ile Gly Leu Ala Ile Tyr (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide W O 97/16570 PCT~US96/17405 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Tyr Ser Ser Asn Leu Ile Thr Gln Gly Cys (2) INFORMATION FOR SEQ ID NO :14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Asn Cys Asp Met Tyr Pro Asp (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Thr Tyr Asp Ile Asn Asp Asn Arg (2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
Trp Leu Lys Lys Arg Gln Val Val Asn Val Leu - W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Glu Thr Ile Pro Ile Thr Gln Asn (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Pro Met Leu Phe Lys Thr (2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide W O 97/16570 PCT~US96/17405 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECUhE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
WO 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
CTTCTAACCG AGGTCGA~AC GTA 23 (2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
W O 97/16570 PCTrUS96/1740 (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CH~RACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 ba~e pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single - (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
(2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: 1 inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
(2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 5 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
(2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
(2) INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs ~ (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Ol igonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
W O 97/16~70 PCTAUS96/17405 (2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
(2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
(2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
(2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Ol igonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
W O 97tl6570 PCTAJS96/17405 (2) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
(2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
(2) INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
(2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:
W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
(2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Ringle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
(2) INFORMATION FOR SEQ ID NO:5~:
(i) SEQUENCE CHARACTERISTICS-(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
TGGCAATGAT ~ATCTCAACC TCTCTCATAA TTGCAGC 37 , (2) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:
(2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
(2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
(2) INFORMATION FOR SEQ ID NO:63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:
(2) INFORMATION FOR SEQ ID NO:64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
(2) INFORMATION FOR SEQ ID NO:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:
LOCATION OF HN SEQUENCES
u01085.gb-vi u01084.gb-vi pifchb83b.gb-vi pifchb83a.gb-vi u01083.gb-vi u01082.gb-vi u01081.gb-vi pifcha8la.gb-vi pifcha8lb.gb-vi pifcha80a.gb-vi u01080.gb-vi pifchb79a.gb-vi pifchb79b.gb-vi u01079.gb-vi u01078.gb-vi u01077.gb-vi pifchb77a.gb-vi u01076.gb-vi u01075.gb-vi u01074.gb-vi u01073.gb-vi pifchb73b.gb-vi pi~chb73a.gb-vi pifchb70a.gb-vi pifcha66a.gb-vi sndha.vi (1957 type sequence) ;
- W O 97/16570 PCTrUS96/17405 Influenza A virus matrix protein (M) nucleotide sequences information references (from Genbank):
flaguml2.gb vi flamm88.gb_vi flamaxl2.gb_vi flampro.gb_vi flamm.gb_vi flama68.gb_vi ~lamlm2a.gb vi flammptp.gb_vi flamk68.gb_vi ~lamwi.gb vi Influenza B virus nonstructure protein (NS) nucleotide sequence information (from Genbank).
flbpa79ns.gb vi flbsi79ns.gb_vi flbnswt.gb_vi flbsi64ns.gb vi flbnd59ns.gb vi flbru69ns.gb vi flbh~73ns.gb vi flbnsy.gb vi flbvi87ns.gb vi flbht84ns.gb vi flbid86ns.gb vi flbgl54ns.gb_vi flbnso.gb_vi RSV A and B nonstructural protein NS2 (lB) and nucleocapsid-associated protein (N) nucleotide sequence information.
Johnson PR and Collins PL. The lB (NS2), lC (NSl) and N
proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSv genomic RNA. J. Gen. Virol. 70:1539, 1989.
W O 97tl6570 PCTtUS96/17405 RSVA transmembrane surface protein F (F) nucleotide sequence information (from Genbank).
rshfl.gb_vi rshfb.gb_vi hru31558.gb_vi hru31559.gb_vi hru31560.gb_vi hri31561.gb_vi hru31562.gb_vi RSVB attachment protein G (G) nucleotide sequence information.
Sullender WM, Muffson MA, Anderson LJ, and Wertz GW:
Genetic diversity of the attachment protein of subgroup B
respiratory syncytial viruses. J. Virol. 65:5425, 1991.
Field of the Invention In general, the present invention relates to assays for hllm~n parainfluenza virus combined with assays for other disease-causing viruses. In particular, the present invention relates to amplification-based and non-amplification-based assays for parainfluenza virus-l, 2 and 3 co~ined with assays for respiratory syncytial virus A and B and influenza virus A
and B.
Back~round ~llm~n parainfluenza virus type one (HPIV-1) is a major cause of lower respiratory tract infections (~RI~ in infants, young children, and the immunocompromised (Henrickson, K. J., l~Lower respiratory viral infections in immunocompetent children," pp. 59-96, In Aronoff SC (ed), Advances in Pediatric Infectious Diseases. ~osby-Year Book, Chicago, Illinois, 1994; Henrickson, K. J., et al., Parainfluenza. In:
Mandell, Bennet D. (ed) PrinciPles and Practices of Infectious Diseases, Edition 4, Churchill Livingston, New York, 1994).
This virus has world-wide distribution and probably contributes significantly to childhood mortality in the developing world (Henrickson, K. J., su~ra, lg94; Henrickson, K. J., et al., suPra, 1994). In the United States, we have ~mo~trated significant morbidity and cost attributable to HPIV-1 epidemics (Henrickson, K. J., et al., "Epidemiology and cost of hllm~n parainfluenza virus types one and two infections in young children," Clin. Infect. Dis. 18:770-9, 1994).
During these epidemics, approximately 100,000 children less than five years of age are seen in emergency rooms and approximately 35,000 are hospitalized at a co~bined cost of approximately $90,000,000 (Henrickson, K. J., et al., suPra, 1994). Currently, there is no specific therapy or vaccine for any HPIV.
We recently reported that HPIV-1 collected over a 26-year period in a single city ~em~trated different genotypes and that one of these genotypes (A) had genotype-~pecific antigenic SUBSTITUTE SHEET ~RULE 26) W O 97/16570 PCT~US96/17405 markers detectable using MAbs and human sera (Henrickson, K.J., "Monoclonal antibodies to human parainfluenza virus type 1 detect major antigenic changes in clinical isolates," J.
Infect. Dis. 164:1128-34, 1991; Henrickson, K. J., et al., "Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: Analysis of 12 clinical isolates," J. Infect. Dis. 164:1128-34, 1992). Subsequently, others found similar antigenic changes in HPIV-1, and one report failed to find genotypes or antigenic markers over a nine-year period (Komada, H., et al., "Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by monoclonal antibodies," J. Gen. Virol. 73:875-84, 1992;
Hetherington, S. V., et al., "Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages," J. Infect. Dis. 169:248-52, 1994).
HPIV-2 outbreaks occur either biennially or yearly (B.
Murphy, et al., "Seasonal pattern in childhood viral lower respiratory tract infections in Melbourne," Med. J. Australia 1:22-24, 1980; M. A. Downham, et al., "Diagnosis and clinical significance of parainfluenza virus infections in children,"
Arch. Dis. Child 49:8-15, 1974; P. Wright, "Parainfluenza viruses." In: R. B. Belshe ed. Textbook of Human Virology.
Littleton, MA: PSG Publishing pp. 299-310, 1984), the majority of them appear in fall to early winter. HPIV-2 is a frequent cause of croup. It causes LRI much less frequently than HPIV-1 and HPIV-3, although the difference may be attributable to the difficulties with viral detection. Approximately 60% of HPIV-2 infections take place in the first 5 years of life;
the peak incidence occurs in the second year, but significant numbers of infants are infected under 1 year of age. Although ~requently overshadowed by HPIV-1 and HPIV-3, HPIV-2 can be predom,n~nt in some years (K. J. Henrickson, et al., "Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children," Clin. Infect. Dis.
18:770-779, 1994).
W O 97/16570 PCT~US96/17405 HPIV-3 is uni~ue among the parainfluenza viruses in its propensi~y to infect young infants less than 6 months of age.
LRI due to HPIV-3 causes approximately 20,000 infants and children to be hospitalized each year in the United States.
About 40% of HPIV-3 infections in the first 12 months of life lead to bronchiolitis and pneùmonia. It is second only to RSV
as a cause of LRI in neonates and young infants. Although endemic throughout the world, this virus also occurs in spring epidemics in North America.
Recent molecular analyses of all four serotypes has revealed more antigenic and genetic heterogeneity than had been appreciated previously (K. J. Henrickson, "Monoclonal antibodies to human parainfluen~a virus type 1 detect major antigenic changes in clinical isolates," J. Infect. Dis.
164:1128-1134, 1991; K. J. Henrickson, et al., "Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: Analysis of 12 clinical isolates," J. Infect. Dis. 166:995-1005, 1992; K. Prinoski, et al., "Evolution of the fusion protein gene of human parainfluenza virus 3," Virus Res. 22:55-69, 1992; M.
Tsurudome, et al., "Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies," Viroloqy 171:38-48, 1989; T. I. Yorlova, et al., " Studies of natural population variability of parainfluenza viruses during their epidemic circulation," Acta Virol.
25:64-70, 1991; K. L. van Wyke Coelingh, et al., "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Viroloqy 143:569-582, 1985; H.
Komada, et al., "Strain variation in parainfluenza virus type 4, J. Gen. Virol. 71:1581-1583, 1990; H. Komada, et al., 'IAntigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by monoclonal antibodies," J. Gen. Virol.
73:875-884, 1992). It appears that all four major HPIV types have virus subgroups that have unique antigenic and genetic characteristics. This includes variability even within HPIV-4 subtypes (H. Komada, et al., supra, 1990). The evolution of W O 97/16570 PCT~US96/1740 --4--these viruses appears to be similar in pattern to in~1uenza B.
Most HPIV strains have type-specific antigens that will react in polyclonal serologic testing as previously described.
However, HPIV-l and HPIV-3 have subgroups (A and B) showing progressive antigenic changes (K. J. Henrickson, suPra, 1991;
K. Prinoski, et al., suPra, 1992). Furthermore, HPIV-1 strains isolated over the past 10 years show persistent antigenic and genetic differences compared to the 1957 type strain (K. J. Henrickson, su~ra, 1991; K. J. Henrickson, supra, 1992; H. Komada, et al., su~ra, 1992). Because of this, standard reference sera prepared to HPIV isolates from the 1950s, or antigen prepared from these same "type" strains, may not react in current serologic assays.
Detection methods for human parainfluenza viruses 1, 2 and 3 currently include standard viral culture of the suspected infected fluid or tissue. This is a slow and expensive process that may take up to ten days to isolate the virus, and in the best hands, may have a sensitivity of only 40-50%. Direct antigen detection using immunofluorescence is also available both in this country and throughout the world, but the detection rate for HPIV by this method is highly variable with sensitivities averaging only in the 50-70~ range and specificities being in the 80-90% range.
A published method concerning the use of an RT-PCR ELISA
for the detection of a human parainfluenza virus type-3 was disclosed by Karron in the Journal of Clinical Microbioloqy (February, 1994, pp. 484-488) entitled "Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: Use of a reverse transcription-PCR-enzyme-immunoassay." The methods described in this paper are specific for an assay to detect human parainfluenza virus type 3 using specific sequences from the HN gene of HPIV-3. However, their methodology is different from the present invention because the present invention allows for the detection of HPIV-1, 2, and 3 in a single test. Furthermore, the present invention allows for the quantitation of HPIV genomic RNA in a clinical sample.
W O 97/16570 PCT~US96/17405 The published method concerning the use of an RT-PCR-ELISA for the detection of influenza A virus was disclosed by Thomas Cherian in the Journal of Clinical Microbiology (March, 1994, page 623-628) entitled "Use of P~R-enzyme immunoassay for identification of influenza A virus matrix RNA in clinical samples negative for cultivable virus." The methods described in this paper are specific for an assay to detect influenza A
virus using specific sequences from the matrix protein gene.
The Cherian method does not allow for the quantitation of influenza A and B virus genomic RNA in a clinical ~ample.
A published method concerning the use of an RT-PCR ELISA
for the detection of respiratory syncytial virus was disclosed by Freymuth in the Journal of Clinical Microbiology (December, 1995, page 3352-3355) entitled "Detection of respiratory syncytial virus by reverse tran~cription PCR and hybridization with a DNA enzyme immunoassay." The methods described in this paper are specific for an assay to detect RSV using specific sequences from the lB and N gene. This method does not allow for the detection of RSV, influenza virus, and HPIV in a single test or allow for the quantitation of RSV genomic RNA
in a clinical sample.
A fast and efficient method for detection and ~uantitation in a biological sample of human parainfluenza virus 1, 2 and 3 along with other disease-causing viruses, such as respiratory syncytial virus A and B and influenza virus A and B, is needed.
Summary of the Invention In one embodiment, the present invention is a method for evaluating a biological sample for the presence or absence of multiple viruses, including human parainfluenza virus, by use of an amplification reaction, such as the polymerase chain reaction. Preferably, this method comprises isolating RNA
from a biological sample and creating cDNA from the isolated RNA. The cDNA is exposed to oligonucleotide primers. If the assay is designed to detect human parainfluenza virus-l infection, the primer is selected from the group consisting of SEQ ID NOs:1-9. In this embodiment of the present invention, W O 97/16570 PCTrUS96/17405 one primer will be in the same 5' - 3' orientation presented in SEQ ID NOs:1-9 and the other primer will be in the inverse complement orientation. The exposure is under condltions in which the primers will amplify a human parainfluenza virus-1 sequence if the sequence is present. The sample is then examined to determined whether an amplification product exists. The presence of an amplification product indicates that the sample contained human parainfluenza virus-1.
The present invention additionally comprises exposing the cDNA to oligonucleotide primers designed to detect additional viruses. These viruses are selected from the group consisting of parainfluenza virus-2 and 3, respiratory syncytial virus A
and B, and influenza virus A and B. Preferred oligonucleotides designed to detect these additional viruses are described in Tables 5, 7 and 8. Preferably, SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58 are preferred primers for respiratory syncytial viruses A and B
and influenza viruses A and B. Tables 5, 7 and 8 also describe suitable probes designed to detect amplification products.
Preferably, SEQ ID NOs:32, 35, 38, 41, 44, 47, 50, 53, 56 and 59 are preferred probes for respiratory syncytial virus A and B
and influenza virus A and B.
The present invention is also a method for directly evaluating a biological sample for the presence or absence of human parainfluenza virus-1 infection along with infections caused by viruses selected from the group consisting of human parainfluenza virus-2 and 3, respiratory syncytial virus A and B, and influenza virus A and B. This method comprises the steps of isolating RNA from a biological sample. This RNA is then exposed to a probe selected from the group of SEQ ID
NOs:1-9 and complements of SEQ ID NOs:1-9 for detection of human parainfluenza virus-1. This exposure is under conditions that allow a hybridization reaction to occur if the probe is in the presence of a complementary nucleic acid.
The sample is then examined for the presence or absence of a hybridization product. The presence of a hybridization product indicates that the sample contains human parainfluenza virus-l nucleic acid and that the patient is infected with parainfluenza virus-l.
Oligonucleotide primers taken from Tables 5, 7 and 8 (as described above) can be used to examine the biological sample for the additional viruses.
In a preferred embodiment of the present invention, the amplification product described above is anchored onto a solid support, such as a microtiter plate, and detected via an enzyme-labeled probe. We have named this method of analyzing a PCR product "PCR-EHA" for PCR-enzyme hybridization assay.
The present invention is also a PCR-ELISA-based method of detecting human parainfluenze virus infection or multiple virus infection of a biological sample comprising the steps of isolating RNA from a biological sample, creating cDNA from the isolated RNA and exposing the cDNA to a primer pair specific for a human parainfluenza sequence and primers specific for respiratory syncytial virus A and B
Qequence or influenza A and B sequence under conditions permitting an amplification reaction. An amplification product will be formed if the sample contains the viruses.
The results of the amplification procedure are exposed to a protein-linked oligonucleotide probe, wherein the probe is of a sequence identical to a virus-specific sequence and wherein the protein-linked probe is attached to a solid support. One then determines whether the amplification product has hybridized to the oligonucleotide.
In another embodiment, the present invention is an improved method of PCR. In one embodiment, the method comprises the step of supplying primers to the reaction in non-equivalent concentrations. Preferable concentrations include an approximately 50 ~M:25 ~M ratio, 25 ~M:50 ~M ratio, 12.5 ~M:50 ~M ratio or 12.5 ~M:25 ~M ratio of 5' primer to 3' prlmer .
In another embodiment, the present invention is also an improved PCR reaction comprising the step of multiply denaturing the sample. Pre~erably, the sample is denatured at least twice for 5 minutes at 95~C.
It is an object of the present invention to detect human parainfluenza virus-1, 2 and 3, respiratory syncytial virus A
and B, and influenza virus A and B sequences in a single tube assay.
It is another object of the present invention to detect hemagglutinin neuraminidase sequences of HPIV-1, 2, or 3, influenza virus A matrix (M) gene sequences, influenza virus B
nonstructural (NS) gene sequences, RSV A lB, nucleocapsid and fusion (F) gene sequences, and RSV B lB, nucleocapsid, and attachment (G) gene sequences.
other objects, features and advantages of the present invention will become apparent after e~min~tion of the specification and claims.
DescriPtion of the Invention In General In one embodiment, the present invention is an assay for hllm~n parainfluenza-1 (HPIV-1). In another embodiment, this assay is combined in an assay for at least one other virus.
Preferably, this assay examines a biological sample for presence or absence of parainfluenza-1, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B.
In one aspect, the present invention involves performing an amplification reaction. Preferably, the amplification reaction is the PCR reaction. However, there are other suitable amplification techniques such as CPR (Cycling Probe Reaction), bDNA (Branched DNA Amplification), SSR (Self-Sustained Sequence Replication), SOA (Strand Displacement Amplification), QBR (Q-Beta Replicase), Re-AMP (Formerly RAMP), NASBA (Nucleic Acid Sequence Based Amplification), RCR
(Repair Chain Reaction), LCR (Ligase Chain Reaction), TAS
(Transorbtion Based Amplification System), and HCS (amplifies ribosomal RNA).
In one embodiment of the invention, this assay comprises the steps of exposing a cDNA created from RNA isolated from a biological sample to oligonucleotide primers chosen from the group described below in Tables 1, 5, 7 and 8. The sample may then be examined for the presence of an amplification product.
W ~ 97/16~70 PCTAUS96/17405 _g_ SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58 are preferable primers.
In another embodiment, the sequences in Tables 1, 5, 7 ~ and 8 may be used to design a probe which would be used to hybridize to nucleic acid sequenceS that are diagnostic for ~ the viruses. In a preferable embodiment, SEQ ID NOS: 32, 35, 38, 41, 44, 47, 50 53, 56 and 59 are preferable probes.
In another embodiment, the present invention is an assay for multiple viruses, preferably human parainfluenza virus-l, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B. This assay comprises the steps of exposing a CDNA created from RNA isolated from a biological sample to oligonucleotide primers specific for the viruses. This exposure is under conditions capable of amplifying a the virus-specific sequences if the sequences are pre~ent. The products of the PCR reaction are then exposed to a protein-linked oligonucleotide probe that has been attached to a solid support via the protein. One then determines whether the amplification product has bound to the solid support, preferably by use of enzymatic labels.
Kits In another embodiment, the present invention is a kit for assaying hllmAn parainfluenza virus type 1 and other viruses, preferably human parainfluenza virus-2 and -3, respiratory syncytial virus A and B and influenza virus A and B. In a preferred embodiment, the kit comprises a pair of primers selected from SEQ ID NOs:1-9. In another embodiment, the kit comprises at least one additional pair of primers designed to amplify respiratory syncytial virus A or B or influenza virus A or B. In a more preferred embodiment of the kit, the kit additionally comprises primers specific for human parainfluenza virus-2 and a pair of primers specific for human parainfluenza virus-3. In a most preferred embodiment of the kit, the kit additionally comprises primers selected from SEQ
ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58 specific for respiratory syncytial virus A and B and influenza virus A and B.
CA 02236022 l998-04-28 W O 97/16570 PCT~US96tl7405 In another em~odiment, the kit additionally comprises oligonucleotide probes specific for parainfluenza virus-l and probes specific for human parainfluenza virus-2 or 3, respiratory syncytial virus A or B, or influenza virus A or B.
In a more preferred embodiment, the kit additionally comprises probes selected from SEQ ID NOs:32, 35, 38, 41, 44, 47, 50 53, 56 and 59 specific for respiratory syncytial virus A and B and influenza virus A and B.
HPIV-1 Probes and Primers The present invention requires the use of a probe or primer pairs that are diagnostic for HPIV-1. To develop these probes or primers, one must first determine what genetic sequences are conserved between the many strains of HPIV-1.
If one were to use a sequence derived from only a few strains, one would risk not detecting an HPIV-1 strain that had mutated slightly from this group.
We had previously investigated genetic diversity in HPIV-1 by sequencing the hemagglutinin neuraminidase (HN) gene of 12 clinical isolates (Henrickson and Savatski, J. Infect. Dis.
166[5]:995-1005, 1992). HN is an important surface protein for this virus. Additionally, we were able to combine 13 HN
sequences obtained from G~nR~nk. (The Ge~R~nk location of the sequences we examined is listed in Appendix 1.) To this group, we added 15 isolates of HPIV-1 that we collected in 1991 during a single fall epidemic.
We compared these 15 new sequences to the known HPIV-1 sequences and looked for highly conserved nucleotide sequences. Our criteria was that the sequence should be greater than or e;3ual to 20 nucleotides in length and contain no nucleotide changes.
Table 1 describes the 9 highly conserved nucleotide sequence regions that we obtained. Table 2 describes the predicted amino acid sequences derived from the conserved nucleotide sequences in Table 1. (The bases and amino acid designations correspond to the numbering system for the HN
gene described in Henrickson and Savatski, J. Infect. Dis.
116[5]:995-1005, 1992).
CA 02236022 l998-04-28 WO 97/16S70 PCT~US96/17405 T~iBLE
HN base pair location: Sequence:
1. 342 - 361: 5~-ATATCAAGGACTATAAACAT (SEQ ID NO:1) 2. 528 - 548: 5'-1l~lG~AGATGTCCCGTAGGA (SEQ ID NO:2) 3. 640 - 673: 5'-TACCTTCATTATCAALla~l~ATGCAATATATGC (SEQ ID NO:3) 4. 675 - 705: 5'-TATTCATCAAACTTAATCACT~G~-ATGTG (SEQ ID NO:4) 5. 754 - 776: 5'-TAAATTCAGATATGTATCCTGAT (SEQ ID NO:5) 6. 798 - 822: 5'-ACCTATGACATCAACGACAACAGGA (SEQ ID NO:6) 0 7. 1173 - 1207: 5~-TGGcTAAAGAAAAGAcAA~ll~l~AAl~~ AAT (SEQ ID NO:7) 8. 1251 - 1276: 5'-GAGACTATTCCAATAACTCAAAATTA (SEQ ID NO:8) 9. 1734 - 1753: 5'-CCTAl~ll~llCAAGACAAG (SEQ ID NO:g) HN gene location: Sequence:
1. 96 aa-101 aa: 5'-ISRTIN (SEQ ID N0:10) 2. 158 aa-164 aa: 5'-FWRCPVG (SEQ ID N0:11) 3. 196 aa-205 aa: 5'-PSLSIGLAIY (SEQ ID N0:12) 4. 207 aa-216 aa: 5'-YSSNLITQGC (SEQ ID N0:13) 5. 234 aa-240 aa: 5'-NCDMYPD (SEQ ID N0:14) 6. 248 aa-255 aa: 5'-TYDINDNR (SEQ ID N0:15) 7. 373 aa-383 aa: 5'-WLKKRQVVNVL (SEQ ID N0:16) 8. 399 aa-406 aa: 5'-ETIPITQN (SEQ ID N0:17) 9. 560 aa-565 aa: 5'-PMLFKT (SEQ ID N0:1~) Therefore, to practice the present invention, one preferably uses a probe or primer pair derived from SEQ ID
NOs:1-9. The following criteria are useful in deriving such a probe or primer.
A. Probe A probe suitable to hybridize with a HN gene sequence will be at least 20 nucleotides in length. Preferably, a probe will be 30 nucleotides in length, and most preferably a probe will be at least 35 nucleotides in length. This length may be taken from any area of the sequence. The probe should preferably have a GC content of approximately 50%. SEQ ID
N0:1 is not a preferable probe because the GC composition is too low.
B. Primers To derive primers from the Table 1 sequences, one must first choose sequences that when amplified would produce a DNA
CA 02236022 l998-04-28 W O 97/16570 PCTnJS96/1740S
segment of sufficient length. For the PCR-ELISA technique that we described below in the Examples, one would need a DNA
segment of at least 100 nucleotides. If one wishes to visualize a PCR fragment on electrophoretic gel, a smaller fragment would suffice. However, for optimum PCR
amplification, a fragment of 100 nucleotides is still preferred. Preferably in both ca~es, the fragment ~hould exceed 150 nucleotides.
Additionally, the primer pair should be in an orientation that permits amplification. The forward primer should be in the 5' - 3' orientation depicted in Table 1. The reverse primer should be in an inverse complement orientation. The primers listed below in the Example (SEQ ID NOs:19 and 20) are examples of suitably oriented primers. One primer (SEQ ID
NO:19) is the 5' - 3' orientation of a portion of SEQ ID NO:2 depicted above. The other primer (SEQ ID NO:20) is the inverse complement orientation of a portion of SEQ ID NO:4.
Additionally, the primer should be chosen so that the two primers are not complementary at the 3' ends. This situation would lead to a hybridization reaction between the primers before the primers hybridize to the substrate material. A
complementary region of equal to or greater than 2 nucleotides will cause an unwanted primer hybridization. Preferably, there will be no complementary region at the 3' end.
Also preferred are primers that do not have internal complementary segments that allow formation of hairpins.
The primers should be at least 20 nucleotides in length.
This 20 nucleotides may be chosen from within the entire length of the sequence reported. For example, a 20 nucleotide length from SEQ ID NO:8 may start with the initial GAG or may start with the fifth nucleotide C. Primers may be longer than 20 nucleotides in length if one wishes.
As described above for probe selection, a GC percentage of approximately 50% is preferred. SEQ ID NO:1 is not a preferred primer because the GC concentration is too low.
The Example below describes a preferable method of isolating nucleic acid suitable to be amplified from a nasal wash. Briefly, the 1 - 2 ml specimens were emptied into CA 02236022 l998-04-28 W O 97/16570 PCT~US96/17405 transport tubes containing 2 ml of minimal essential medium supplemented with bovine serum albumin, amphotericin B, penicillin G, and gentamicin. These specimens are centrifuged - and the supernatants divided and refrigerated.
RNA is preferably isolated from these supernatant samples - by adding a guanidinium solution described below in the Examples. Other methods known in the art of isolating RNA
would also be suitable.
The following are preferred primer pairs for PCR
reactions. The numbers in Table 3 and 4 refer to the SEQ ID
NO. For example, "2" indicates SEQ ID NO:2.
GROUP A GROUP B GROUP C GROUP D GROUP E GROUP F GROUP G
2 + 3 3 + 5 4 + 5 5 + 7 6 + 7 7 + 8 8 + 9 2 + 4 3 + 6 4 + 6 5 + 8 6 + 8 7 + 9 2 + 5 3 + 7 4 + 7 5 + 9 6 + 9 2 + 6 3 + 8 4 + 8 2 + 7 3 + 9 4 + 9 2 + 8 2 + 9 HN-specific oligonucleotide primer pairs and probes that are preferred for PCR-EHA are listed below in Table 4.
Human Parainfluenza Probes and Primers for PCR-EHA-based Assay The present invention is also a PCR-EHA-based method of assaying a biological sample for any type human parainfluenza.
This assay depends on a protein-linked oligonucleotide specific for a human parainfluenza gene sequence linked to a solid support via the protein molecule.
The method begins with exposing a biological sample to a primer pair specific for any human parainfluenza gene. We have described above how to isolate a primer pair specific for the HN gene. The human parainfluenza genome is known to comprise a variety of genes and many of these would be CA 02236022 l998-04-28 .. ,~ ~
UJ ,,~ ~
,_ .~
~ CD ~D
Cl ~ <D
d~
p C~ ~ (D 1' co a~
.~ + + + +
O ~ ~ ~ ~ ~
+ + + + +
o ~
.t + + + + + +
c~ N N N N N N
-- W O 97/16570 PCTrUS96/17405 diagnostic for human parainfluenza. One would first obtain a nucleotide sequence of a human parainfluenza gene that is diagnostic for human parainfluenza as opposed to other infectious agents and cellular components. This could be facilitated by searching gene banks for any known sequence similar to the candidate sequence. If no matches are found, then the candidate sequence is likely to be specific to HPIV.
One would then construct a suitable primer pair from this gene sequence. Criteria listed above will be useful in constructing such a primer pair. One would then expose RNA
isolated from a suitable biological sample to this primer pair under conditions suitable for PCR amplification.
Separately, one would obtain a probe, using the criteria described above, specific for a human parainfluenza gene sequence. This probe should be attached to a protein molecule capable of binding a solid support. We have described above a procedure wherein BSA is attached to an oligonucleotide and used to bind a solid support. However, other protein molecules may be equally suitable. To determine whether a protein molecule is as suitable for the present invention as BSA, one would run a reaction with a candidate protein in parallel to a reaction with BSA and determine whether the candidate protein linked oligonucleotides attached to the plate with the same efficiency as the BSA-linked oligonucleotides.
The protein-linked oligonucleotide is then attached to a solid support in preparation for a PCR-EHA assay as described above. One then determines whether the amplification product i9 present, thus indicating that the biological sample is infected with human parainfluenza virus.
HPIV-l AssaY
To perform the method of the present invention, one must first select a probe and primer pair as described above and expose the cDNA described above to the primer pair.
After amplification, the PCR product is detected with the corresponding probe.
Bioloqical SamPle The probe or primers derived from the Table 1 conserved sequences are exposed to a biological sample that may contain HPIV-1 virus. This biological sample is preferably a nasal wash made from nasal secretions. Preferably, one would prepare the nasal wash by standard methods known to one of skill in the art. Preferably, as described in Henrickson, J.
Viol. Methods, 46:189-206, 1994 or Hall and Douglas, J.
Infect. Dis., 131:1-5, 1975.
However, other biological fluids such as nasal a~pirates or pleural fluid, preferably respiratory fluids, would also be suitable. Other body fluids such as blood or spinal fluid would all be suitable for the present invention.
The present invention is especially useful for the diagnosis of HPIV-l in immunocompromised children or adults.
These patients might preferably be diagnosed by broncho alveolar lavage.
Reverse Transcription Reaction Once RNA is isolated from the biological sample, one needs to perform a reverse transcription reaction to create a cDNA template for the primers.
A suitable reverse transcription reaction requires that the RNA sample be exposed to reverse transcriptase enzyme and deoxyribonucleotides so that a cDNA molecule may be created that corresponds to the initial RNA molecule.
Preferably, a reverse transcription reaction is performed as described below in the Examples.
A. PCR Reaction Preferably, one would choose to use a pair of primers and examine the final product for presence of a PCR amplification product. This e~Ami~tion could involve examining the products of the reaction on an electrophoretic gel and determining whether an amplified product of the appropriate size had been created. One of skill in the art of molecular biology will be aware of many protocols designed to optimize W O 97/16570 PCT~US96/17405 PCR reactions. Particularly useful protocols are described in PCR Protocols, Ed. M. Innis, et al. Academic Press, San Diego.
Most preferably, the PCR reaction will be coupled to an EHA procedure. As described below, one would anchor the PCR
amplification product to a solid support and ~mi ne the support for the presence of the PCR product. This procedure could be done in several ways. We will describe two of the most preferable ways below.
PCR-EHA Method A. In this method, one first attaches the amplified product to a solid support, such as a microtiter dish. For example, a streptavidin-coated plate may be provided. One of the selected primers may be attached to a biotin molecule so that an amplification product will be labelled with biotin and bind to the streptavidin plate.
The plate and product are then expo~ed to an HN-specific oligonucleotide probe containing a segment of the HN sequence.
This probe is attached to a marker enzyme, such as horseradish peroxidase (HRP), which may be detected via its enzymatic properties.
This protocol is described in detail in the Examples below.
PCR-EHA Method B. In PCR-EHA method B, one would attach a protein molecule capable of binding to the solid support, such as BSA, to an HN-specific oligonucleotide probe. The plate is coated with these protein-attached oligonucleotides that are available to hybridize with an amplified product. This amplified product is preferably attached to a label molecule, such as biotin, that is capable of being detected. In one embodiment, the biotin-labelled PCR product may be complexed to a streptavidin-horse radish peroxidase conjugate. One may then detect this complex with the appropriate substrate. A preferred method of performing this method is described below:
One must first derivitize the 5' phosphorylated oligonucleotide probe (oligolink derivitization reagent, PIERCE). Preferably, one would place 20 ug/ul of 5'-phosphorylated oligonucleotide in a clean 1.5 ul microcentrifuge tube. Remove 200 ul of the derivitization reagent and transfer to a vial containing EDC (ethyl-3[3-dimethyl-aminopropyl] carbodiamide).
Centrifuge the tube 3 seconds in a microcentrifuge to collect reactants in the bottom of the tube. Incubate the tube at 50~C for 30 minutes with constant mixing.
Resuspend the OligoLink~ matrix by vortexing until no solid is visible in the bottom of the tube. To an assembled spin column add 160 ul of matrix. Place the column in a microcentrifuge tube and centrifuge briefly (5 seconds) to remove the excess water. After spinning, carefully push the bottom cap onto the column. Discard the water from the collection tube.
Following the incubation period, add 81 Ul OligoLinkTM
binding buffer to the tube containing the derivitization oligonucleotide. Mix well and transfer the entire contents to the spin column containing the OligoLink~ matrix. Screw the top cap onto the spin column and invert the column to mix the reactants. Agitate the tightly capped spin column at room temperature for 15 minutes. Following the 15 minute incubation period, spin the column for 2 seconds with caps in place to collect the reactants in the bottom of the column.
Carefully remove top and bottom caps. Place the spin column in a collection tube and centrifuge for 10 seconds.
To the spin column add 500 ul OligoLink~ binding buffer.
Spin for 10 seconds. Wash the OligoLink~ matrix by adding 500 ul ethanol wash buffer. Spin 10 seconds. To spin the column and another 500 ul of ethanol wash buffer, followed by 1.0 ul of DTT solution. Replace the top cap on the spin column and invert several times to suspend the matrix in the reductant. Incubate 10 minutes with occasional mixing.
Following the reduction step, spin column 2 seconds with caps in place to collect reactants in the bottom of the column then remove top and bottom caps. Place spin column in a collection tube and spin for 10 seconds. Wash the excess DTT
from the column by adding 500 ul ethanol wash buffer. Spin 10 seconds.
Repeat the ethanol wash 3 more times using 500 ul of ethanol wash buffer each time. Add 160 ul H2O (preheated to 55~C), and incubate the entire column at 55~C for 5 minutes.
- Remove caps and place the column in a clean 1.5 ml collection tube. Spin the column for 20 seconds. Discard eluate.
One should then prepare a maleimide activated BSA/oligonucleotide probe complex (Imject Maleimide Activated Bovine Serum Albumin~, Pierce). Add 4 ml H2O to 2 mg activated BSA. Immediately mix the oligo and 0.2 ml BSA, incubate at room temperature for 2 hours and hold at -20~C.
To coat the ELISA plate, one may follow the following procedure. Preferably Costar, EIA/RIA plates, Medium Bind-in 3591, are obtained. Make up a solution containing 30 ul oligo-BSA complex in 15 ml coating buffer. (Coating buffer is 0.2M Carbonate-Bicarbonate buffer, pH 9.4). Add 100 ul/well of this solution and incubate at 4~C overnight. The next morning, empty plate and wash with PBS 3 times.
To block the ELISA plate, one would preferably use the following procedure: Add 300 ul/well blocking solution.
(Blocking solution is 5X Denhardt's solution, 1% gelatin tEIA
grade, BIORAD], 250 ug/ml herring sperm DNA.) Incubate overnight at 4~C. Remove blocking solution by aspiration next morning.
One then performs an enzyme hybridization assay.
Preferably, add 70 ul/well of premixed solution for solution hybridization. Mix 5 ul denatured PCR product (denature at 95~C, 5 minutes, keep on ice, 10 minutes) and 65 ul hybridization buffer. Incubate at 42~C 1 hour.
A preferable hybridization buffer is:
5X saline sodium phosphate EDTA
5X Denhardt's solution 1 pmol/100 ~l HRP-labeled HPIV-1 or HPIV-2, or HPIV-3 HN specific probe Wash 20 times with PBS at 37~C and 8 times with PBS
containing 0.05% Tween-20.
To analyze the reaction products, one would typically dilute strepavidin-HRP-conjugate 1:1000 with PBS containing 0.05% Tween-20. Add 200 ul/well and incubate at room W O 97/16570 PCTrUS96/17405 temperature for 30 minutes. Wash 5 times with PBS containing 0.5% Tween-20. Add 200 ul/well TMB-ELISA substrate buffer (Life Technologies) in the dark. Incubate at room temperature for 15 minutes with gentle agitation. Stop with 50 ul/well l.ON H2SO4. Incubate with gentle agitation for 5 minutes.
To interpret results, one may read optical density (OD) at 450 nM in 30 minutes. Samples with an O.D. greater than or equal to the mean of the negative control plus 3a of the negative control are considered positive. If the O.D. is less than this, the sample is considered negative.
To quantitate the copy nu~mber of HPIV-1 RNA in the sample, plot the EHA O.D. of the standard curve and fit each sample O.D. to this plot.
Quantification Standard The following method is useful in constructing a quantification standard: HPIV-1 virus RNA is synthesized from HPIV-1 virus genomic RNA by reverse transcription. The cDNA
is amplified with a primer pair of HNlB (ACT CTG GAC TCA AGA
ATG AGA AAT, SEQ ID NO:28) and HN2A (CAT ATT TGA CAA ATA GGC
AGG CAT, SEQ ID NO:29) to yield a 2070 bp HN gene product.
The PCR product and plasmid PCRTMII (Invitrogen, San Diego, CA) are ligated according to the supplier's protocol. A clone is obtained and named PCRTMII 2-1. This clone contains the 2070 bp HPIV-1 HN gene insert. The clone is, preferably, confirmed first by BamHI, XbaI, BamHI/XbaI digestion and then by sequencing with USB sequences PCR product sequencing kit (United States Biochemical, Cleveland). PCRTMII2-1 DNA is transcribed to RNA with SP6 RNA polymerase (Promega, Madison, WI). The RNA is e~m,n~d on denatured agarose gel, quantitated on a spectrophotometer to obtain copy number and frozen at -80~C. A known copy number of the transcript is introduced into virus genomic RNA lysis buffer and isolated with the same procedure as virus genomic RNA isolation when it is used as a quantitative standard.
Positive and negative controls which included transcript RNA from plasmid PCRTMII2-1 and PCRTMII are added at each assay. The cutoff value is calculated from the mean CA 02236022 l998-04-28 absorbance obtained from a group of seronegative samples plus three standard deviations. Copy number from subject samples are determined from the absorbances obtained ~rom a dilution - series of an RNA HN gene construct of know copy number described previously.
B. Probe HYbridization Reaction If one chooses to use a probe hybridization reaction as an HPIV-1 assay, one must expose the probe and viral genomic RNA under conditions known in the art to allow hybridization between the probe and HPIV-1 sequence. Preferable conditions are those described in the Examples for hybridization in the EHA reaction.
The sample is then examined for the presence of the hybridization product. Preferably, this e~m;n~tion would comprise labeling the probe and determining whether a double-stranded labelled product is present at the end of the assay procedure.
HPIV-1, 2 and 3 AssaY
If one wishes to assay for HPIV-1, 2 and 3, one could use the method of the present invention in combination with known sequences used as primers for HPIV-2 and 3. Table 5 below describes known HPIV-2 and 3 sequences. We have demonstrated that primers and probes from these known sequences are capable of amplifying and detecting HPIV-2 and 3 by RT-PCR-EHA.
HPIV-1 Assa~ Kit A kit to detect HPIV-1 would contain either a selected probe or selected PCR primers labelled as described below.
Additionally, substrate materials could be included, such as TMB if horseradish peroxidase is the enzyme label. A HN-specific oligonucleotide, preferably labelled, should beincluded.
HPIV-1, 2, and 3 RT-PCR-EHA Kit The present invention is also a kit for the detection of HPIV-1 or, alternatively, for the detection of HPIV-1, 2 and W O 97/16570 PCT~US96/17405 3. The kits are different depending on which of the three preferred PCR methods for detecting HPIV sequences one wishes to use:
PCR-EHA Method A
The kit for HPIV-1, 2 and 3 would comprise three pairs of primers for HPIV-1, HPIV-2 and HPIV-3 and three different probes specific for HPIV-l, HPIV-2 and HPIV-3. Preferable probes and primers are described in Table 5. The probes would all be enzymatically labelled. Preferable enzyme labels are also described in Table 5. Preferably, the kit also contains substrates for enzyme detection such as TMB (3',3',5',5 tetramethylbenzidine), bromocresol purple, and PNPP
(p-nitrophenylphosphate).
The procedure for using this kit would be as follows:
1. The three pairs of primers for HPIV-1, HPIV-2, and HPIV-3 are added in each of 3 tubes. A PCR reaction is then performed and PCR products are obtained.
2. The HPIV-1 probe, HPIV-2 probe and HPIV-3 probe are labeled with HRPO, alkaline phosphatase (AP) and urease, respectively.
3. One would then perform the EHA procedure described below in the Examples. One would preferably add 200 ~l/well TMB-ELISA substrate for HPIV-1 detection in one well, PNPP for HPIV-3 detection in another well and bromoresol purple for HPIV-2 detection in the third well.
PCR-EHA Method B
A different kit is necessary if one wishes to use PCR-EHA
method B. This kit, would provide three pairs of primers for HPIV-1, 2 and 3 and three HN-specific oligonucleotide probes for HPIV-1, 2 and 3. The oligonucleotides would all be attached to a protein molecule suitable for binding a solid support, such as BSA. One primer from each primer pair should be labelled enzymatically. The general procedure of PCR-EHA
Method B is as follows:
W O 97/16570 PCT~US96/17405 1. Three pairs of primers for HPIV-l, HPIV-2, and HPIV-3 are added in each PCR tube. A PCR reaction amplifies any HPIV-l, 2 or 3 sequences.
- 2. BSA/HPIV-l oligonucleotide complex, BSA/~PIV-2 oligonucleotide complex, and BSA/HPIV-3 oligonucleotide complex are coated on microtiter plates separately.
3. The products of step 1 are combined with the labelled probes and hybridization products are detected. The PCR-EHA procedure B is described above.
Alternatively, one may wish to use PCR-EHA method B with probes that are not specific for the HN protein. A suitable kit for this method would provide at least one pair of primers specific for human parainfluenza virus genome and one protein-linked oligonucleotide probe specific for the hllm~n parainfluenza virus amplification product. As above, one primer from the primer pair should be enzymatically labelled.
The general procedure of PCR-EHA method B, as described above, would then be followed. Preferably, one would provide three pairs of primers and three probes specific for sequences found in human parainfluenza-1, 2 and 3 in the kit.
PCR Method C
The third PCR method is simply a PCR reaction and visualization of the PCR product. For the third PCR method, one would simply need to provide three pairs of primers for ~IPIV-1, 2 and 3. After the amplification reaction the PCR
products would be examined on a electrophoretic gel, preferably a 2~ agarose gel, and visualized. This visualization is preferably via ethidium bromide staining.
If the primers and probes described in Table 5 are used, the PCR product size for HPIV-l is 180, for HPIV-2 is 244, and for HPIV-3 is 278 bp or 151 bp, respectively. The density of the band is examined by densitometry and compared with a standard.
We have successfully used the kit described above to assay biological samples for human parainfluenza virus-1, 2 and 3.
W O 97/16~70 PCTAUS96/17405 T~iBLE 5 PRIMERS AND PROBES USEDIN HPIV-1,HPIV-2,HPIV-3PCR-EHA KIT
S~PCR ENZYME
SUBTYPE SF~IIE' PRODUCT I ~R~I IIG SUBSTRATE
HPIV-1 5' Primer: ATT,TCT,GGA,GAT,GTC,CCG, TAG,GAG,AAC (SEQ ID NO:19) 180 3' Primer: Bio~n-CAC,ATC,CTT,GAG,TGA, TTA,AGT,TTG,ATG,A (SEQ ID NO:20) Probe: TAC,CTT,CAT,TAT,CAA,TTG,GTG, ATG,CAA,TAT,ATG (SEQ ID NO:21) HRPO TMB
HPIV-2 5' Primer: GTC,TCA,TGG,ATT,CCG,ATG, ATT,CAC,AGC,AA (SEQ ID NO:22) 244 3' Primer: GAT,GTA,CGC,TGC,ATC,ATG, CAG,AAG,CAG,A (SEQ ID NO:23) Probe: AGG,ATA,TGC,ATA,CTG,GGA,GCA, Blull~ ~:~dl TGT,CCA,ACA,CCA (SEQ ID NO:24) Urease Purple HPIV-3 5' Primer: TAT,GGA,CAA,TAA,TCC,TGG, TGT,TAT,TAT,C(SEQ ID NO:25) 278 3' Primer: TAA, m, CAC,TAA,TGA,ATT,TCC, TM,GAT,C(SEQ ID NO:26) 5' Primer: AAG,ATC,CAA,ATG,GCA,TCG, 151 GAT,AAT,A (SEQ ID NO:64) 3' Primer: TAA,TTT,CAC,TAA,TGA,ATT,TCC, TAA,GAT,C(SEQ ID NO:65) Probe: GTG,AAT,ACA,AGG,~;TT,CTT,ACA, ATT,CAG,AGT,CAT (SEQ ID NO:27) AP PNPP
Probes and Primers for Res~iratorY SYncYtial Virus A and B and Influenza Virus A and B
The present invention requires that the biological sample be examined for the presence of at least one virus selected from the group of respiratory syncytial virus A and B and influenza virus A and B. The Examples below demonstrate suitable primers and probes in Tables 7 and 8.
Preferably, primers will be selected from SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58. Preferably, probes will be selected from SEQ ID NOs:32, 35, 38, 41, 44, 47, 50, 53, 56 and 59.
The multiple virus assay would be performed identically to the assays described above except that multiple primers or probes will be included in the assay mix.
CA 02236022 l998-04-28 W O 97/16570 PCT~US96/17405 MISMATCHED PRIMERS AND MULTIPLE DENATURATION IMPROVE THE
DETECTION OF HUMAN PARAINFLUENZA VIRUS BY QUANTITATIVE REVERSE
TRANSCRIPTION-PCR-ENZYME HYBRIDIZATION ASSAY.
The final step in reverse transcription-PCR-enzyme hybridization assay (RT-PCR-EHA) is the enzymatic modification of a colourless substrate solution to a colored one. The optical density (OD) of this color change is measured on a spectrophotometer and represents the outcome of the EHA
portion of the RT-PCR-EHA assay. Increasing the OD of positive samples in comparison to negative and control samples would result in increased sensitivity and specificity of the RT-PCR-EHA.
As described below in the Examples, we have developed two methods to increase the optical density of EHA. In comparison with conventional methods using matched PCR primers or conventional PCR product denaturation, the optical density i5 increased 3.6 times by using mismatched PCR primer concentration and 6.1 times by using multiple denaturation of the PCR products. Our data demonstrates that mismatched PCR
primer concentration and multiple denaturation of the PCR
products significantly increase the optical density of EHA
positive samples without increasing the background. The two methods will greatly benefit the application of RT-PCR-EHA and any PCR based diagnostic test including the diagnosis of infectious diseases, cancer, genetic disease, metabolic disorders, etc.
Therefore, the present invention is also an improved method of PCR. The method comprises the step of supplying mismatched primer concentration to a PCR reaction. For example, one of the Examples below demonstrates the efficacy of mismatched primer concentrations where the 5' to 3' primer ratio is 50 ~M:25 ~M, 25 ~M:50 ~M, 12.5 ~M:50 ~M and 12.S
~M:25 ~M. By "approximately" we mean that the ratio is within 10% of the given ratio.
The present invention is also an improved method of PCR
comprising the step o~ denaturing the initial reaction mixture at least twice, preferably at 95~C for 5 minutes for each W O 97/16570 PCT~US96/17405 denaturation. In a most preferable version of the reaction, the sample is denatured at least 4 times.
Exam~les ExamPle 1. Detection and Ouantification of HPIV-1 HN Gene Am~lification Products bY a NonisotoPic Svstem: RT-PCR-EHA.
The following describes our procedure for assaying nasal wash samples for HPIV-1:
A. Collection of nasal wash sPecimens.
Standard nasal washes were carried out on patients suspected of having a parainfluenza virus infection.
The specimens averaged 1-2 ml and were immediately emptied into transport tubes containing 2 ml of minimum essential medium (MEM) supplemented with 0.5% bovine serum albumin, gentamicin (5 ~g/ml).
Transport tubes were kept at room temperature 0.5-3 hours in the emergency room before being refrigerated at 4~C.
The specimens were centrifuged at 2000 x g for 15 minutes, and the supernatants were then divided. 0.5-1 ml aliquots were refrigerated at 4~C, until frozen at -80~C later that day.
B. Construction of the auantitation standard.
The quantitation standard was a 2070-base RNA transcript of a plasmid designated PCRTMII2-1. To construct this standard, HPIV-l virus RNA was synthesized from HPIV-1 virus genomic RNA by reverse transcription. The cDNA was amplified with a primer pair of HNlB (ACT CTG GAC TCA AGA ATG AGA AAT, SEQ ID NO:28) and HN2A (CAT ATT TGA CAA ATA GGC AGG CAT, SEQ
ID NO:29) to yield a 2070 bp HN gene product.
The PCR product and plasmid PCRTMII (InVitrogen, San Diego, CA) were ligated under standard conditions.
Transformation of INVaF'-competent cells (InVitrogen, San Diego, CA) with the ligated plasmid was carried out according to the suppliers protocol. A clone was obtained and named PCRIMII2-1. This clone contained the 2070 bp HPIV-1 HA gene insert.
CA 02236022 l998-04-28 W O 97/l6570 PCTAUS96/17405 The clone was checked first by BamHI, XbaI, BamHI/XbaI
digestion and then by sequencing with USB sequenase PCR
product sequencing kit (United States Biochemical, Cleveland).
PCRTMII2-1 DNA was transcribed to RNA with SP6 RNA
polymerase tPromega, Madison, WI). The RNA was viewed on a denatured agarose gel, quantitated on a spectrophotometer to obtain correct copy number, and frozen at -70~C.
C. RNA Isolation Into a sterile 1.5 ml microfuge tube, 0.5 ml guanidinium solution was added to 100-200 ul tissue culture supernatant or the clinical nasal wash described above. The guanidinium solution was:
Guanidinium (iso)thiocyanate 4 M
Sodium Citrate, pH 7 25 mM
Sarcosyl 2% (w/v) 2-mercaptoethanol 0.1 M
The samples were homogenized by vortexing. 50 ~1 (1/10 volume) of 2M sodium acetate pH 4 was added. 500 ~1 (1 volume) water saturated phenol (pre-warmed) was added. 100 ~1 (1/5 volume) chloroform isoamyl alcohol (49:1) was added.
The mixed solution was vortexed thoroughly and then cooled on ice 5 minutes. The suspension was centrifuged in a microfuge at full speed for 15 minutes at 4~C. The RNA was present in the top aqueous phase whereas DNA and proteins were in the interphase and phenolic phases. The aqueous phase was transferred to a microfuge tube and 500 ~1 (1 volume) isopropanol was added. The samples were stored at -70~C for at least 60 minutes and then spun at 4~C for 15 minutes. RNA
precipitated and formed a white-yellow pellet at the bottom of the tube. The supernatant was removed and the RNA pellet was washed twice with 70% ethanol in DEPC H20. DEPC H20 iS 0.196 Diethylpyrocarbonate in water, shaken well, incubated 2 hours 37~C, and autoclaved.
The RNA pellet was vacuum dried briefly for 10-15 minutes and then dissolved by vortexing in 50 ~l DEPC H2O containing O.5 ,ul RNase inhibitor (Boehringer Mannheim, 50 units/ml).
The RNA was stored at -20~C or -70~C.
CA 02236022 l998-04-28 D. Reverse TranscriPtion (RT) Reaction A RT master mix was prepared:
RT Master MixVolume (~l)Final Cone~ntration 25 mM MgCl2 4 ~l 5 mM
lOX PCR buffer (PEC) 2 lX
dGTP 2 1 mM
dATP 2 1 mM
dTTP 2 1 mM
0 dCTP 2 1 mM
RNase in-h-ibitor (20 units/ml) 1 1 u/~l MULV reverse transcriptase 1 2.5 u/~l Random h~Am~rs l 2.5 u/~1 18 ~l/sample 18 ~1l RT master mix was added to a thermalcycling tube.
2 ~1 RNA from the sample described above was added. 2 ~1 quantitation standard RNA with 10, 50, lO0, lOOO, 5000, lO,OOO
copies respectively, were added and kept at room temperature for 10 minutes. The samples were incubated 42~C for 60 minutes, then 99~C for 5 minutes, then held at 5~C.\
E. PCR AmPlification A PCR master mix was prepared:
PCR master mix Volume (~l) Final Concentrations 25 mM MgCl, 2 ~l 2 mM
lOX PCR buffer 4 lX
sterile distilled H2O 31.5 37.5 ~l/sample PCR sample tubes were prepared:
PCR master mix 37.5 ~l -Upstream primer PF526 l l.0 ~M
Downstream primer PR678 biotin 1 1.0 ~M
cDNA lO
Ampli Taq DNA polymerase 0.5 2.5 units/50 ~1 50 ~1 W ~ 97/16570 PCTAUS96/17405 The samples were overlayed with 40 ~1 mineral oil. The tubes were placed in a 70~C prewarmed thermal cycler within 2 minutes of adding Ampli Taq to reduce nonspecific binding of primers and production of nonspecific products. Hot start is optional (see Ampli Taq directions).
Sequence of primer PF 526: ATT TCT GGA GAT GTC CCG TAG
GAG AAC (SEQ ID NO:l9).
Sequence of primer PR 678: Biotin-CAC ATC CTT GAG TGA
TTA AGT TTG ATG AT (SEQ ID NO:20).
The thermalcycling program was as follows:
1. 95~C, 2 minutes (1 cycle) 2. 95~C, 1 minute; 55~C, 45 seconds; 72~C, 45 seconds, (2 cycles) 3. 94~C, 1 minute; 60~C, 45 seconds; 72~C, 45 seconds, (28 cycles) 4. 72~C, 7 minutes (final extension) F. Denature PCR Product To denature the DNA, the samples were incubated at 95~C
for 5 minutes and then kept on ice.
G. EHA
300 ~l/well blocking solution was added to Reacti-Bind Strepavidin Coated Polystyrene Strep Plates (Pierce Catalog #15120) and incubated overnight at 4~C. The blocking solution was removed by aspiration.
Blocking solution:
5X Denhardt's solution 1% gelatin (EIA grade, BIOR~D) 250 ~g/ml herring sperm DNA (Promega) 70 ~l/well of premixed solution was added for solution hybridization. 5 ~1 denatured PCR product was mixed with 65 ~l hybridization buffer and incubated 42~C, 1 hour.
Hybridization buffer:
5X saline sodium phosphate EDTA
5X Denhardt's solution 1 pmol/100 ~l HRP-labeled HPIV-l HN specific probe The sequence of HRP-labeled HPIV-1 HN specific probe was HRP-TAC, CTT, CAT, TAT, CAA, TTG, GTG, ATG, CAA, TAT, ATG (SEQ
ID NO:21). The sample was washed 20 times with lX PBS 0.05 Tween-20. 200 ~l/well TMB-EHA substrate (Life Technologies Catalog #15980-014) was added, and the sample was incubated 15 minutes 20~C in the dark. The reaction was stopped by adding 50 ~l/well lN H2SO4. The O.D. of the sample was measured at 450 nm.
H. InterPretation of re~ults Samples with O.D.'s greater than or equal to the mean of the negative control plus at least 3 times ~ of the negative control and greater than 0.100 O.D. are considered positive.
If the O.D. is less than this, it is considered negative.
To quantitate the copy number of HPIV-1 RNA in the original sample, the EHA O.D. of the standard curve was compared and the copy number with each sample was read. Table 6, below, discloses data obtained in the Example described above. Nasal samples were independently cultured and identified. Both positive and negative samples were analyzed according to the present invention.
RT-PCR-EHA
Mean of HPIV
Specimen Group No. Specimens No. Positive No. Negative copy/mL
virus culture pogitive 9 9 0 239607 virug culture negative 40 4 36 36528 The 4 positive samples from the virus culture negative samples were found to have a mean HPIV copy/ml of 36528 transcripts. The other negative samples had no copies of HPIV
transcripts.
W O 97/16570 PCT~US96/17405 ExamPle 2. Preparation of Primers and Probes for use in Virus AssaY for Influenza A and B and RespiratorY SYncYtial Virus A
and B.
Tables 7 and 8 describe primers and probes that we have successfully used in individual assays for influenza A and B
virus detection and respiratory syncytial virus A and B
detection by quantitative RT-PCR-EHA.
The probes and primers were prepared as follows:
Sequences from Genbank and published sources were ~m;n~d (see Appendix 2) and appropriate probes and primers were developed (see Tables 7 and 8). Individual assays were performed as described above for HPIV with the same criteria for success. The results of the RT-PCR-EHA for RSV-A, B and influenza A and B are similar to those found for HPIV-l, 2 and 3. All primers and probes listed in Tables 7 and 8 were successful. (The numbering referred to in Tables 7 and 8 for "position of sequence" begins at the 5' end of the gene.) Example 3. Diaqnosis of Human Parainfluenza Virus Type 1, Type 2, Type 3, Respiratory SyncYtial Virus A and B, and Influenza Virus A and B Infection bY RT-PCR-EHA Usinq Mixed Primers in a Sinqle Tube Multiplex Assay.
Here, we describe an RT-PCR-EHA for the detection of hllm~n parainfluenza virus type 1 (HPIV-1), type 2 (HPIV-2), type 3 (HPIV-3), respiratory syncytial virus type A (RSV-A), type B (RSV-B), influenza virus A and B RNA with mixed primers in a single tube assay. In comparison with separated RT-PCR-EHA, the single tube multiplex EHA-RT-PCR demonstrated the same sensitivity and specificity. This method will represent an important tool for the timely and sensitive diagnosis of HPIV-1, HPIV-2, HPIV-3, RSV-A, RSV-B, influenza virus A and B
virus infections.
~ '' g ~q o P.~
s ~ ~ ", ~ ~ ~ o~ o ~ ~ o r-- ~ oo ~ ~ oO 1~ 00 E
t t t ~ ~ D t c t ~- t ~- t- ' c t ' C ~ C c C~ C c . Y, -- . a t ~ ~ . ~ t . ' d r ' ~ ' V C~ ~ ¢ ' ~ ' V E-' ~s~ c~s~ ~'b~ ~s~ c'- ~ c'- ~
o o e~ .o O ~ .0 o ~ .o o E- . O E- . O
m ~ ~ ¢ ~ ~ ¢ ~ P~
~ ~ ~ ~ ,o ~ ~ ~o ~ ~ ~~ ~ ~ 2 ~ ~ ~~
t_ ~ ~ ~V et ~ 1~ ~~ ~ ~~ ~ ~ ~ ~ ~ ~
o ~ ~ rq r~ r~ r" r"
¢ ~ ¢ ¢ ¢ Z Z Z Z Z Z
Zo ~
W O 97/16570 PCTrUS96/17405 ~ ~ Z
g ~_ ~Z ~ ~
~ ~ o~ ~ o -- ~ ~ C~ _ ~ o~ ~, --z ~ ~ D X ~ ~r X ~ X Y .Y ,=
p~ ~ G o ~ ~ O G ~ 2 ~'" 4 ~Z ~ ~ ~ Z ~
A. Materials and Methods Virus stocks. HPIV-1 (HA-2, strain C39; American Type Culture Collection, Rockville, Maryland, USA), HPIV-2 (LRS-76 clinical isolate, 1991, Milwaukee), HPIV-3 (LRS-75 clinical 5 isolate, 1991, Milwaukee), RSV-A (A2 strain; American Type Culture Collection), RSV-B (RSV; strain 9320; American Type Culture Collection), influenza virus A (LRS-147 clinical isolate, 1991, Milwaukee), influenza virus B (Jones strain;
American Type Culture Collection) were used and prepared in 10 our laboratory by standard protocols.
Viral qenomic RNA isolation. Viral genomic RNA was extracted from frozen nasal wash specimens by previously described methods. Briefly, samples were treated with guanidinium-isothiocyanate (4 M) in sodium citrate (25 mM) 15 buffer (pH 7.0) with 0.5% sarcoryl and 0.1 M ~-mercaptoethanol; 0.1 volume of 2 M sodium acetate was added together with 1 volume of water-saturated phenol and 0.2 volume of chloroform-isoamyl alcohol (49:1). After centrifugation, RNA was extracted in the a~ueous phase, and 20 the phenol-chloroform extraction was repeated once more. The RNA was then precipitated with isopropanol at -20~C for 1 hour. After centrifugation, the pellet was washed twice with 70% ethanol and was dissolved in 50 ~1 of diethyl pyrocarbonate-treated water containing 20 U of RNase 25 inhibitor.
cDNA sYnthesis. cDNA was synthesized from random hexamers by incubation with murine leukemia virus (MuLV) reverse transcriptase (Perkin-Elmer Cetus, Norwalk, Connecticut USA) and 1 mM each deoxynucleoside triphosphates 30 at 42~C for 60 minutes and 99~C for 5 minutes and was soaked at 5~C for 5 minutesFifteen nanograms each of viral RNA from virus stock was used for a single test.
Amplification of cDNA bY PCR. For PCR amplification, 6 1/2 pairs of primers (RSV A and B share a 3' primer) from 35 highly conserved sequences of the HPIV-1, 2, and 3 HN genes, the lB and N genes from RSV-A and B and the M gene from influenza virus A and NS gene from influenza B were used for amplification.
W O 97/16570 PCT~US96/17~05 The primers for the HPIV-l HN gene are HPIV-1 PF 526 (SEQ
ID NO:19) and HPIV-1 PR 678 (SEQ ID NO:20); for HPIV-2 HN gene were HPIV-2 PF 301 (SEQ ID NO:22) and HPIV-2 PR 545 (SEQ ID
NO:23), for HPIV-3 HN gene were HPIV-3 PF 321 (SEQ ID NO:25), 5 and HPIV-3 PR 471 (SEQ ID NO:26).
~ For the RSVA IB and N gene we used RSVlB 967 (SEQ ID
NO:48) and RSVAN1136 (SEQ ID NO:49), for RSVB lB and N gene we used primers RSVB960 (SEQ ID NO:54) and RSVAN1136 (SEQ ID
NO:43), for influenza virus A M gene we used primers INFAM32 (SEQ ID NO:30) and INFAM243 (SEQ ID NO:34), and for influenza virus B NS gene we used primers INFBNS748 (SEQ ID NO:45) and INFBNS967 (SEQ ID NO:46).
The assay mixture contained 10 mM Tris-HCl, 2 mM MgCl2, O.2 mM (each) deoxynucleoside triphosphates, O.2 ~M (each) 15 primers, and 2.5 U of AmpliTaq DNA polymerase (Perkin-Elmer Cetus). After denaturation at 95~C for 2 minutes, aliquots were then amplified by two cycles at 95~C for 1 minute, 55~C
for 45 seconds, and 72~C for 45 seconds and 29 cycles of 95~C
for 1 minute, 60~C for 45 seconds, and 72~C for 45 seconds and 20 were then held at 72~C for 7 minutes.
The PCR products were analyzed by electrophoresis on a 2%
agarose gel in TBE (Tris-borate-EDTA) buffer at 80 V for 1 hour and 15 minutes and were stained with ethidium bromide.
The PCR products were also analyzed using liquid enzyme 25 hybridization (EHA).
B. Results The PCR products were analyzed by electrophoresis on 2%
agarose gel. The seven PCR products for HPIV-l, HPIV-2, HPIV-30 3, RSV-A, RSV-B, influenza virus A and influenza virus B were 180 bp, 245 bp, 151 bp, 189 bp, 196 bp, 227 bp, and 244 bp.
Only a specific band showed up in response to each set of primers. In comparison with RT-PCR with one pair of primers, the band obtained from RT-PCR with mixed prlmers in single 35 tube reaction showed the same size and the same sensitivity.
The results obtained in our experiments demonstrate the possibility for rapid diagnosis of HPIV-1, HPIV-2, HPIV-3, RSV-A, RSV-B, influenza virus A, and influenza virus B
W O 97/16570 PCTrUS96/17405 infections by RT-PCR with mixed primers in single tube reaction.
The PCR product from all seven viruses was also detected using specific probes (SEQ ID NOs:21, 24, 27, 50, 56, 32 and 5 47) to each virus in EHA.
Example 4. Mismatched PCR Primer Concentration Improves the Det~ction of HPIV-1, 2, or 3 bY Ouantitative RT-PCR-EHA.
In the Example below, we demonstrate that varying the 10 ratio of primer concentration drastically improves PCR
performance.
A. Materia~s and Methods Construction of the auantitation standard. To construct 15 a standard, HPIV-1, 2, or 3 virus cDNA was synthesized from HPIV-1, 2, or 3 virus genomic RNA by reverse transcription.
The cDNA was amplified using the primer pairs (e.g., HPIV3 5'0013 ~AGG, AGT, A~A, GTT, ACG, CAA, T (SEQ ID NO:60)) and HPIV-3 3'1957 (TGA, TTA, CTT, ATC, ATA, TAC, TTG (SEQ ID
20 N0:61)) to yield a 1945 bp HPIV-3 HN gene product). The PCR
product and plasmid PCR~II (Invitrogen, San Diego, CA) were ligated under standard conditions. Transformation of INVaF'-competent cells (Invitrogen, San Diego, CA) with the ligated plasmid was carried out according to the supplier's protocol.
25 PCR~II HPIV-1, 2 or 3 HN DNA was transcribed to RNA with SP6 RNA polymerase (Promega, Madison, WI). The RNA was examined on a denatured Agarose gel, ~uantitated on a spectrophotometer to obtain the copy number and frozen at -70~C.
cDNA svnthesis. cDNA was synthesized from random 30 hexamers by incubation at 42~C for 60 minutes, 99~C for 5 minutes, and soaked at 5~C for 5 minutes with MuLV reverse transcriptase (Perkin-Elmer Cetus, Norwalk, CT) and 1 mM dNTP.
Fifteen nanograms of virus RNA from virus stocks was used for a single test.
Amplification of cDNA bY PCR. For PCR amplification, primers from highly conserved sequences of the HPIV-1, 2, or 3 HN gene (e.g., PF 321-AAG, ATC, CAA, ATG, GCA, TCG, GAT, AAT, A, SEQ ID NO:62, from bp 321 to 345 sense), and PR 471- TAA, TTT, CAC, TAA, TGA, ATT, TCC, TAA, GAT, C, SEQ ID NO:63, from bp 443 to 471, antisense) were used for amplification. HPIV-1, 2, or 3 primers (e.g., PR 471) were biotinylated at the 5' end (Operon, Alameda, CA). To optimize the PCR primer 5 concentration, 11 pairs of different primer concentrations ~ were tested in RT-PCR-EHA using HPIV-1, 2, or 3 specific primer pairs (Table 9). The PCR mixture contained 10 mM Tris, 2 mM MgCl, 0.2 mM dNTP, and 2.5 U Ampli Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT). After denaturation at 95~C
10 2 minutes, aliquots were then amplified by two cycles of 95~C
for 1 minute, 55~C for 45 seconds, 72~C for 45 seconds, 34 cycles at 95~C for 1 minute, 60~C for 45 seconds, 72~C for 45 seconds, and hold at 72~C for 7 minutes. After final extension at 72~C for 7 minutes, PCR products were denatured 15 by heating at 95~C for 5 minutes and then kept on ice (standard conditions). To optimize the effect of heat denaturation on the RT-PCR-EHA, PCR products were denatured by using different heating conditions and then kept on ice (Table 10). Positive and negative controls which included transcript 20 RNA from plasmid PCR~ HPIV-1, 2, or 3 HM and PCR~II were added to each assay.
The PCR products were analyzed by electrophoresis on 2~
agarose gel in TBE buffer, 80 volts for 1 hour 15 minutes, and stained with ethidium bromide.
Detection and quantitation of PCR product by enzYme-hybridization assaY (EHA). To detect and quantitate the PCR
products, 96-well microplates were coated with streptavidin.
Wells were then filled with 300 ~l of a blocking solution containing 5x Denhardt's solution, 1% gelatin, 250 ~g/ml 30 sheared herring sperm DNA (Promega, Madison, WI) at 4~C.
Immediately before use, the blocking solution was aspirated from each well and 5 ~l of the previously made PCR products and 65 ~l of a hybridization solution containing 5x saline sodium phosphate EDTA, 5x Denhardt's solution, and 1 pmol/100 35 ~l of HRP-labeled HPIV 1, 2, or 3 specific probe (e.g., HPIV-3 HN probe 369-GTG, AAT, ACA, AGG, CTT, CTT, ACA, ATT, CAG, AGT, CAT, SEQ ID NO:27, from 369 to 401, sense) were added to individual wells. A capture and hybridization reaction was then carried out in the well for 1 hour at 42~C. The 96-well microplate was washed with PBS cont~n~n~ 0.05% Tween-20. 200 ~1 of substrate solution TMB-ELISA, (Life Technologies), was added to each well. After 15 minutes the reaction wa~ stopped with 1 N H2SO4 and the optical density of each well was measured at 450 nm on a spectrophotometer (Biotek, EL3~.
Results and Discussion Table 9 tabulates the results o~ varying primer concentration:
OPTlMeATlON OF PCR PRIMER CONCENTRATION IN RT-PCR-EHA
PCR Primer 1 2 3 4 5 6 7 8 9 10 11 PF321, 5'Primer~ 50 25 12.5 6.25 50 50 50 25 12.5 6.25 12.5 PR471,3'Primert 50 25 12.5 6.25 25 12.5 6.25 50 50 50 25 15 ~ 'Ir~
Optcal Densityt 0.2 0.257 0.026 0.021 0.455 0.047 0.012 0.38 0.652 0.244 0.71 Primer wu~.~ in ~uM.
I spccific primers at450 ~a~ ' _ (A450).
tHPlV-3 specific primers.
In comparison with conventional matched PCR primers (50 ~M each), mismatched PCR primer concentration (5' primer PF
321 at concentration 12.5 ~M, and biotinylated 3' primer PR471, at concentration 25 ~M) showed a 3.59 times increase in optical density. Mismatched primer concentration may create more biotin-labeled PCR product which will be captured by the streptavidin coated plate and thereby increase the value o~
optical density reading.
MULTIPLE DENATURATION OF THE PCR PRODUCT IMPROVES THE
DETECTION OF HPIV-1, 2, OR 3 BY QUANTITATIVE RT-PCR-EHA.
DENATURE CONDmON
Denature TL~ ., 95~C, 5' 95~C, 10' 95~C, 95~C, 95~C, 95~C, 5' 95~C, 5' (~C) and time (min) 1S 20' S
Time Kept on icc (min) 10' 10' 10' 10' 10' 10~ 10 35 Time(s) x1 x1 x1 x1 x2 x3 x4 Value of optical densi~ 0.185 0.145 0.162 0.182 0.561 0.584 1.126 SU~ ITE SHEET (RULE 26) In comparison with the conventional heat denaturation method (#1, Table 10) the optical density using the double denaturation method (#5, Table 10) increased 3.03 times and the four time denaturation method (#7, Table 10) showed a 6.05 5 times higher OD. However, lengthening the denaturation time did not increase the optical density. Multiply denatured PCR
product demonstrated more single-stranded DNA on agarose gel.
This would allow more binding of viral-specific probes (also single-stranded) during the EHA portion of the RT-PCR-EHA.
Increased probe binding would then lead directly to increased OD in the test well.
_ CA 02236022 l998-04-28 - W 097/16570 PCT~US96/17405 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Henrickson, Kelly J.
Fan, Jiang (n.m.i.) (ii) TITLE OF INVENTION: VIRUS ASSAY METHOD
(iii) NUMBER OF SEQUENCES: 65 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Quarles & Brady (B) STREET: 411 East Wisconsin Avenue (C) CITY: Milwaukee (D) STATE: Wisconsin (E) COUNTRY: U.S.A.
(F) ZIP: 53202-4497 (v) COM~Ul'~K READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COM~Ul~: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1. 25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Baker, Jean C.
(B) REGISTRATION NUMBER: 35,433 (C) REFERENCE/DOCKET NUMBER: 650053.91037 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (414) 277-5000 (B) TELEFAX: (414) 271-3552 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ~ (D) TOPOLOGY: 1 inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOhOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
- W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Ile Ser Arg Thr Ile Asn (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Phe Trp Arg Cys Pro Val Gly (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Pro Ser Leu Ser Ile Gly Leu Ala Ile Tyr (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide W O 97/16570 PCT~US96/17405 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Tyr Ser Ser Asn Leu Ile Thr Gln Gly Cys (2) INFORMATION FOR SEQ ID NO :14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Asn Cys Asp Met Tyr Pro Asp (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Thr Tyr Asp Ile Asn Asp Asn Arg (2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
Trp Leu Lys Lys Arg Gln Val Val Asn Val Leu - W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Glu Thr Ile Pro Ile Thr Gln Asn (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Pro Met Leu Phe Lys Thr (2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide W O 97/16570 PCT~US96/17405 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECUhE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
WO 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
CTTCTAACCG AGGTCGA~AC GTA 23 (2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
W O 97/16570 PCTrUS96/1740 (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CH~RACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 ba~e pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single - (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
(2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: 1 inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
(2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 5 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
(2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
(2) INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs ~ (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Ol igonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
W O 97/16~70 PCTAUS96/17405 (2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
(2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
(2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
(2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Ol igonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
W O 97tl6570 PCTAJS96/17405 (2) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
(2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
(2) INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
(2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: l inear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:
W O 97/16570 PCT~US96/17405 (2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
(2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Ringle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
(2) INFORMATION FOR SEQ ID NO:5~:
(i) SEQUENCE CHARACTERISTICS-(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
TGGCAATGAT ~ATCTCAACC TCTCTCATAA TTGCAGC 37 , (2) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:
(2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
(2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
(2) INFORMATION FOR SEQ ID NO:63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:
(2) INFORMATION FOR SEQ ID NO:64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
(2) INFORMATION FOR SEQ ID NO:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:
LOCATION OF HN SEQUENCES
u01085.gb-vi u01084.gb-vi pifchb83b.gb-vi pifchb83a.gb-vi u01083.gb-vi u01082.gb-vi u01081.gb-vi pifcha8la.gb-vi pifcha8lb.gb-vi pifcha80a.gb-vi u01080.gb-vi pifchb79a.gb-vi pifchb79b.gb-vi u01079.gb-vi u01078.gb-vi u01077.gb-vi pifchb77a.gb-vi u01076.gb-vi u01075.gb-vi u01074.gb-vi u01073.gb-vi pifchb73b.gb-vi pi~chb73a.gb-vi pifchb70a.gb-vi pifcha66a.gb-vi sndha.vi (1957 type sequence) ;
- W O 97/16570 PCTrUS96/17405 Influenza A virus matrix protein (M) nucleotide sequences information references (from Genbank):
flaguml2.gb vi flamm88.gb_vi flamaxl2.gb_vi flampro.gb_vi flamm.gb_vi flama68.gb_vi ~lamlm2a.gb vi flammptp.gb_vi flamk68.gb_vi ~lamwi.gb vi Influenza B virus nonstructure protein (NS) nucleotide sequence information (from Genbank).
flbpa79ns.gb vi flbsi79ns.gb_vi flbnswt.gb_vi flbsi64ns.gb vi flbnd59ns.gb vi flbru69ns.gb vi flbh~73ns.gb vi flbnsy.gb vi flbvi87ns.gb vi flbht84ns.gb vi flbid86ns.gb vi flbgl54ns.gb_vi flbnso.gb_vi RSV A and B nonstructural protein NS2 (lB) and nucleocapsid-associated protein (N) nucleotide sequence information.
Johnson PR and Collins PL. The lB (NS2), lC (NSl) and N
proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSv genomic RNA. J. Gen. Virol. 70:1539, 1989.
W O 97tl6570 PCTtUS96/17405 RSVA transmembrane surface protein F (F) nucleotide sequence information (from Genbank).
rshfl.gb_vi rshfb.gb_vi hru31558.gb_vi hru31559.gb_vi hru31560.gb_vi hri31561.gb_vi hru31562.gb_vi RSVB attachment protein G (G) nucleotide sequence information.
Sullender WM, Muffson MA, Anderson LJ, and Wertz GW:
Genetic diversity of the attachment protein of subgroup B
respiratory syncytial viruses. J. Virol. 65:5425, 1991.
Claims (51)
1. A method for evaluating a biological sample for the presence or absense of human parainfluenza virus 1 infection, comprising the steps of (a) isolating RNA from a biological sample, (b) creating cDNA from the isolated RNA, (c) exposing the cDNA to a pair of oligonucleotide primers selected from SEQ ID NOs:1-9 or inverse complements of SEQ ID NOs :1-9 under conditions in which the primers will amplify a human parainfluenza virus 1 sequence if the human parainfluenza virus 1 is present, wherein an amplification product is produced if the human parainfluenza virus 1 is present; and (d) determining whether the amplified product is present.
2. A method for evaluating a biological sample for the presence or absence of human parainfluenza virus 1 infection comprising the steps of (a) isolating RNA from a biological sample, (b) exposing the RNA to a labelled probe selected from SEQ ID NOs:1-9 under conditions wherein a hybridization reaction between the probe and a complementary sequence can occur, and (c) examining the reaction to determine whether a hybridization product exists.
3. The method of claim 1 wherein the biological sample is a respiratory secretion.
4. The method of claim 1 wherein step (d) comprises attaching the product of step (c) to a marker enzyme and examining the products of step (c) for the marker.
5. The method of claim 6 wherein the marker enzyme is horse radish peroxidase.
6. The method of claim 2 wherein the primers or probes are SEQ ID NOs:19 and 20.
7. The method of claim 1 additionally comprising the step of attaching the amplification product to a solid support.
8. The method of claim 8 wherein the solid support is a microtiter dish.
9. The method of claim 1 wherein the amplification product is detected by hybridization of an oligonucleotide probe specific for a hemagglutinin neuraminidase sequence.
10. The method of claim 9 wherein the oligonucleotide probe is labelled with an enzyme.
11. A kit for the detection of human parainfluenza virus 1 comprising a pair of primers selected from SEQ ID NOs:1-9.
12. The kit of claim 11 further comprising a pair of primers specific for human parainfluenza virus 2 and a pair of primers specific for human parainfluenza virus 3.
13. The kit of claim 11 additionally comprising a HN-specific oligonucleotide probe.
14. A method of detecting human parainfluenza virus infection in a biological sample comprising the steps of (a) isolating RNA from a biological sample, (b) creating cDNA from the isolated RNA, (c) exposing the cDNA to a primer pair specific for a human parainfluenza sequence under conditions suitable for nucleic acid amplification, wherein an amplification product is formed if the sample contains human parainfluenza virus, and (d) determining whether the amplification product is present by exposing the step (c) products to protein-linked oligonucleotide probes under conditions suitable for hybridization between complementary nucleic acid sequences and examining the probes for the presence of a hybridization product, wherein the oligonucleotide probe is of a sequence identical to a human parainfluenza sequence and wherein the oligonucleotide probe is attached to a solid support.
15. The method of claim 14 wherein the oligonucleotide probe is linked to BSA.
16. The method of claim 15 wherein at least one primer of the primer pair is enzymatically labelled.
17. A kit for the method of claim 14 comprising a pair of primers specific for a human parainfluenza sequence and a protein-linked oligonucleotide probe specific for a human parainfluenza sequence.
18. The kit of claim 17 wherein at least one of the primers is labelled.
19. A method for evaluating a biological sample for multiple virus infection comprising the steps of (a) isolating RNA from a biological sample, (b) exposing the RNA to at least one labelled probe selected from SEQ ID NOs:1-9 and to labelled probes designed to hybridize to respiratory syncytial virus or influenza virus under conditions wherein a hybridization reaction between the probe and a complementary sequence can occur, and (c) examining the reaction to determine whether a hybridization product exists.
20. A method for evaluating a biological sample for the presence or absence of multiple virus infections, comprising the steps of (a) isolating RNA from a biological sample, (b) creating cDNA from the isolated RNA, (c) exposing the cDNA to a pair of oligonucleotide primers selected from SEQ ID NOs:1-9 or inverse complements of SEQ ID NOs:1-9 under conditions in which the primers will amplify a human parainfluenza virus 1 sequence if the human parainfluenza virus 1 is present, wherein an amplification product is produced if the human parainfluenza virus 1 is present;
(d) exposing the cDNA to at least one additional pair of oligonucleotide primers under conditions designed to amplify respiratory syncytial virus or influenza virus sequences if the viruses are present, wherein an amplification product is produced if the respiratory syncytial virus or influenza virus are present; and (e) determining whether the amplified products are present.
(d) exposing the cDNA to at least one additional pair of oligonucleotide primers under conditions designed to amplify respiratory syncytial virus or influenza virus sequences if the viruses are present, wherein an amplification product is produced if the respiratory syncytial virus or influenza virus are present; and (e) determining whether the amplified products are present.
21. The method of claim 20 additionally comprising the step of exposing the cDNA to primer pairs specific for human parainfluenza virus 2 and human parainfluenza virus 3.
22. The method of claim 20 wherein the biological sample is examined for both respiratory syncytial virus and influenza virus.
23. The method of claim 22 wherein the biological sample is examined for respiratory syncytial viruses A and B and influenza viruses A and B.
24. The method of claim 23 wherein the primers are selected from the group consisting of SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58.
25. The method of claim 20 wherein the biological sample is a respiratory secretion.
26. The method of claim 20 wherein step (e) comprises attaching the products of steps (c) and (d) to a marker enzyme and exmaining the products of steps (c) and (d) for the marker.
27. The method of claim 23 wherein step (e) comprises exposing the results of steps (c) and (d) to oligonucleotide probes specific for human parainfluenza virus 1, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B.
28. The method of claim 20 wherein the biological sample is evaluated for the presence or absence of human parainfluenza virus-2 and 3.
29. The method of claim 28 wherein the biological sample is evaluated for the presence of respiratory syncytial viruses A and B and influenza viruses A and B.
30. The method of claim 29 wherein the probes are selected from the group consisting of SEQ ID NOs:32, 35, 38, 41, 44, 47, 50, 53, 56 and 59.
31. The method of claim 20 additionally comprising the step of attaching the amplification product to a solid support.
32. The method of claim 31 wherein the solid support is a microtiter dish.
33. The method of claim 20 wherein the amplification product is detected by hybridization of an oligonucleotide probe specific for a hemagglutinin neuraminidase sequence.
34. The method of claim 33 wherein the oligonucleotide probe is labelled with an enzyme.
35. A kit for the detection of multiple viruses comprising a pair of primers selected from SEQ ID NOs:1-9 and at least one pair of primers designed to amplify respiratory syncytial virus A or B or influenza virus A or B.
36. The kit of claim 35 additionally comprising a NH-specific oligonucleotide probe.
37. The kit of claim 35 further comprising a pair of primers specific for human parainfluenza virus 2 and a pair of primers specific for human parainfluenza virus 3.
38. The kit of claim 37 further comprising primers specific for respiratory syncytial virus A and B and influenza virus A and B.
39. The kit of claim 38 wherein the primers are selected from SEQ ID NOs:30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57 and 58.
40. The kit of claim 38 additionally comprising oligonucleotide probes specific for the HN gene of HPIV1, 2 or 3, the influenza A virus M gene, the influenza virus B NS
gene, the respiratory syncytial virus 1B, N and F genes, and the RSVB 1B, N and G genes.
gene, the respiratory syncytial virus 1B, N and F genes, and the RSVB 1B, N and G genes.
41. The kit of claim 40 wherein the probes are selected from SEQ ID NOs:32, 35, 38, 41, 44, 47, 50 53, 56 and 59.
42. The kit of claim 39 additionally comprising a pair of primers specific for human parainfluenza virus 2 and a pair of primers specific for human parainfluenza virus 3.
43. The kit of claim 39 wherein the HN-specific oligonucleotide probe is labelled.
44. The kit of claim 39 wherein the HN-specific oligonucleotide probe is linked to a protein suitable for attaching the probe to a solid support.
45. The kit of claim 39 wherein the HN-specific oligonucleotide probe is labelled.
46. A method of detecting multiple virus infection in a biological sample comprising the steps of (a) isolating nucleic acid from a biological sample, (b) exposing the nucleic acid or cDNA created from the nucleic acid to primer pairs specific for human parainfluenza virus-1, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B sequences under conditions suitable for nucleic acid amplification, wherein an amplification product is formed if the sample contains any of the viruses, and (c) determining whether the amplification product is present by exposing the step (b) products to protein-linked oligonucleotide probes under conditions suitable for hybridization between complementary nucleic acid sequences and examining the probes for the presence of a hybridization product, wherein the oligonucleotide probe is of a sequence identical to a viral sequence.
47. A kit for the method of claim 46 comprising a pair of primers and probes specific for human parainfluenza virus 1, 2 and 3, respiratory syncytial virus A and B and influenza virus A and B.
48. A method for PCR amplification of a nucleic acid molecule, comprising the improvement of supplying 5' and 3' primers of unequal concentrations.
49. The method of claim 48 wherein the ratio of 5' to 3' primer is selected from the group consisting of approximately 50:25, 25:50, 12.5:50 and 12.5:25.
50. A method of PCR amplification of a nucleic acid molecule comprising the improvement of denaturing the reaction mix, comprising a 5' and a 3' primer and a template nucleic acid molecule, at least two times.
51. The method of claim 50 wherein the reaction mix is denatured at least four times for 5 minutes at 95°C.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/552,907 | 1995-11-03 | ||
| US08/552,907 US5744299A (en) | 1995-11-03 | 1995-11-03 | Human parainfluenza virus-1 assay |
| US08/691,045 US6015664A (en) | 1995-11-03 | 1996-08-01 | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
| US08/691,045 | 1996-08-01 | ||
| PCT/US1996/017405 WO1997016570A1 (en) | 1995-11-03 | 1996-11-01 | Virus assay method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2236022A1 true CA2236022A1 (en) | 1997-05-09 |
Family
ID=29407646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2236022 Abandoned CA2236022A1 (en) | 1995-11-03 | 1996-11-01 | Virus assay method |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2236022A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116479175A (en) * | 2023-03-13 | 2023-07-25 | 广州国家实验室 | Detection system, kit and method for detecting human parainfluenza virus nucleic acid |
-
1996
- 1996-11-01 CA CA 2236022 patent/CA2236022A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116479175A (en) * | 2023-03-13 | 2023-07-25 | 广州国家实验室 | Detection system, kit and method for detecting human parainfluenza virus nucleic acid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU716222B2 (en) | Virus assay method | |
| US5744299A (en) | Human parainfluenza virus-1 assay | |
| Osiowy | Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay | |
| JP3744548B2 (en) | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 | |
| AU2021250940B2 (en) | Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acids in single-plex or multiplex assays | |
| US20100279273A1 (en) | Nucleic acid sequences for the amplification and detection of respiratory viruses | |
| JP2011167199A (en) | Composition and assay to detect nucleic acid of type a and type b influenza virus | |
| EP1613779A2 (en) | Compositions and methods for determining the presence of SARS coronavirus in a sample | |
| CZ288064B6 (en) | Oligonucleotide primers for detection of HIV-1, their use and a kit containing thereof | |
| US5968732A (en) | Isothermal transcription based assay for the detection and genotyping of dengue virus | |
| WO1995002690A1 (en) | Nucleotide sequences and process for amplifying and detection of hepatitis b virus | |
| CA2073989A1 (en) | Immobilization of nucleic acids | |
| GB2432419A (en) | Influenza A virus detection method | |
| CA2236022A1 (en) | Virus assay method | |
| EP1310565B1 (en) | A process for detecting nucleic acid target molecules using an enzyme-linked probe capture assay and a kit therefor | |
| JPH11507239A (en) | Nucleic acid probes and amplification oligonucleotides for NEISSERIA species | |
| JP5164850B2 (en) | Oligonucleotide, its use, detection method and kit for diagnosing the presence of H5 and N1 genes of influenza A virus | |
| WO1996006191A2 (en) | Primers and probes for the amplification and detection of cmv nucleic acid | |
| WO1996021675A2 (en) | Capturing of microorganisms using complement components | |
| EP0879894A2 (en) | Sample preparation for nucleic acid based diagnostic tests | |
| WO2018077891A1 (en) | Method for detecting rsv by strand-invasion based dna amplification | |
| CA2236613A1 (en) | Sample preparation for nucleic acid based diagnostic tests |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |